Introduction {#s1}
============

*Mycobacterium tuberculosis* (*Mtb*), a bacterium that causes 1.5 million deaths a year ([@bib59]; [@bib70]), differs from many bacterial pathogens in its infection strategy, which depends on an unusual cell envelope ([@bib11]). The importance of this structure is evident from the fact that at least a quarter of the genes in the *Mtb* genome are involved in its construction and regulation ([@bib19]). The mycobacterial cell wall consists of peptidoglycan (PG) covalently bound to a layer of arabinogalactan sugars, which is in turn covalently bound to a layer of mycolic acid lipids that make up an outer membrane ([@bib1]; [@bib11]).

While the chemistry of this cell envelope is increasingly well defined, its regulation is poorly understood. Regulated cell wall changes are essential for *Mtb* to cause disease ([@bib19]; [@bib59]) and are thought to contribute to phenotypic antibiotic tolerance. TB therapy requires 6--12 months of drug treatment. This is likely due, in part, to drug tolerance like that observed in stressed, non-growing Mtb cultures ([@bib68]). Because stressed Mtb also exhibits cell wall changes such as thickening, differential staining and chemical alterations ([@bib7]; [@bib14]; [@bib58]), it seems probable that the cell wall changes contribute to antibiotic tolerance. Importantly, starved, antibiotic tolerant Mtb cells have been shown to be less permeable to antibiotics ([@bib57]). However, the regulatory mechanisms that induce cell wall changes in response to stress and contribute to impermeability and tolerance have not been described.

The peptidoglycan (PG) layer provides protection and shape-defining structure to cells of almost all bacterial species. This layer is constructed by transpeptidases and glycosyltransferases, which attach new precursors to the existing cell wall; and several types of catabolic PG hydrolases, which break bonds in the existing PG. PG enzymes must be tightly regulated to promote cell growth and septation without compromising the wall integrity, and to restructure the cell wall to withstand stresses ([@bib37]). Accordingly, a large number of regulators in the cytoplasm, inner membrane and periplasm coordinate and control the activities of the PG enzymes, either directly or indirectly ([@bib37]; [@bib63]).

In addition to the dedicated regulators, many PG synthases and hydrolases work together in complexes and regulate each others' enzymatic activity through protein-protein interactions ([@bib5]; [@bib28]; [@bib61]). Notably, some PG hydrolases have lost their enzymatic activity and function only as regulators: EnvC in *E. coli* is missing catalytic residues from its active site but contributes to cell septation by activating the PG amidases AmiA and AmiB ([@bib65]; [@bib74]).

In this work we study the predicted PG hydrolase, CwlM, and find that its essential function is regulatory rather than enzymatic. We find that CwlM is located in the cytoplasm, is phosphorylated by the essential Serine Threonine Protein Kinase (STPK) PknB, and functions to stimulate the catalytic activity of MurA, the first enzyme in the PG precursor synthesis pathway. In nutrient-replete conditions CwlM is phosphorylated. Using *in vitro* biochemistry we show that phosphorylated CwlM (CwlM\~P) increases the rate of MurA catalysis by \~30 fold. In starvation, CwlM is dephosphorylated and in this state does not activate MurA, which has very low activity alone ([@bib72]). Importantly, we find that over-activation of MurA in the transition to starvation causes increased sensitivity to multiple classes of antibiotics. Finally, a phylogenetic analysis implies that CwlM protein evolution was driven by localization to the cytoplasm.

Results {#s2}
=======

*cwlM* (Rv3915, MSMEG_6935) is predicted to be essential for growth in *Mtb* ([@bib75]), is highly conserved among mycobacteria, and is annotated as an N-acetylmuramoyl-L-alanine amidase of the AmiA/LytC family (hereafter: PG amidase), a type of PG hydrolase. CwlM~TB~ has been shown to have PG amidase activity ([@bib18]); however, key residues that coordinate the catalytic Zn^2+^ are not conserved in CwlM from both *Mtb* and *Msmeg* ([@bib73]) ([Figure 1A](#fig1){ref-type="fig"}), implying that it is inefficient as an enzyme. This is supported by our observation that overexpression of CwlM did not affect cell viability ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}): overexpression of highly active PG hydrolases usually results in cell lysis ([@bib64]). Thus, we hypothesized that CwlM's essential function might not be enzymatic. Certain PG hydrolases in *E. coli* function as regulators of other PG hydrolases rather than as enzymes ([@bib65]). We hypothesized that CwlM may have a similar role in activating an essential enzyme.

CwlM is essential for growth in *M. smegmatis*, but may have a non-enzymatic function {#s2-1}
-------------------------------------------------------------------------------------

To confirm the essentiality of *cwlM* in *Msmeg* we constructed a strain (See [Supplementary file 1](#SD1-data){ref-type="supplementary-material"} for full descriptions of all strains), Ptet::*cwlM,* in which the only copy of *cwlM* is under control of an anhydrotetracyline (Atc)-inducible promoter. Depletion of CwlM by removing Atc results in cell death ([Figure 1B](#fig1){ref-type="fig"}). Microscopy of CwlM-depleted cells shows that they are short, implying a defect in elongation. To assess polar elongation ([@bib2]; [@bib62]), we stained cells with an amine reactive dye (ARD) ([@bib2]) and cultured them to allow new, unstained polar cell wall to form before imaging ([Figure 1C](#fig1){ref-type="fig"}). We found that CwlM-depleted cells fail to elongate normally ([Figure 1D,E,F](#fig1){ref-type="fig"}).10.7554/eLife.14590.003Figure 1.CwlM's essential function promotes polar growth, but not through enzymatic activity.(**A**) Alignment of the active-site proximal regions of the enzymatic domain of PG amidases. The Zn^2+^-coordinating residues are boxed: the conserved aspartate/ glutamates in green, and the degenerate histidine/ arginines in red. (**B**) Colony forming units (CFU) of the Ptet::*cwlM* (CB82) strain grown with (+CwlM) or without (−CwlM) Atc inducer from Time 0. Data from all experiments throughout is from three biological replicates and error bars are the standard deviation, unless otherwise noted. (**C**) Cartoon of the amine reactive dye (ARD) staining method showing polar growth after staining, with a diagram of how cell length and polar growth were measured for Figures 1EF and 2EF. (**D**) Overlaid micrographs of the Ptet::*cwlM* strain grown with (+CwlM) or without (−CwlM) Atc for 9 hr, stained with ARD, grown 3 hr and imaged with a 488/530 filter (green) and in phase (red and black). Representative cells from several images used in **E** and **F** were pasted together, the scale is conserved between images. (**E**) The length of \~230 cells from each condition in (**D**). Two biological replicates were used for all microscopy experiments, unless noted. (**F**) The length of the longer unstained pole of the cells in (**E**), line indicates the median in (**E**) and (**F**). \*\*\*\* p value \<0.0001. (**G**) Growth curves showing the OD~660~ of WT (L5::*cwlM*, CB236) and amidase-ablated (L5::*cwlM* D209A E331A, CB239) strains growing in 7H9, and a bar graph showing the calculated doubling times of these strains (inset). n.s. -- not significant. The p value was 0.51 by the student's t-test**DOI:** [http://dx.doi.org/10.7554/eLife.14590.003](10.7554/eLife.14590.003)10.7554/eLife.14590.004Figure 1---figure supplement 1.Overexpression of CwlM.Colony forming units of *Msmeg* strains overexpressing wild-type (CB193), the amidase ablated allele of *cwlM* (CB194), and the amidase domain alone (CwlM ∆PG binding domains, CB202), and an α-His western blot showing that these proteins are expressed. Proteins were expressed from Atc-inducible promoters on episomal vectors.**DOI:** [http://dx.doi.org/10.7554/eLife.14590.004](10.7554/eLife.14590.004)

To determine if CwlM requires amidase activity for its essential function, we mutated the active site aspartate and glutamate that coordinate the catalytic Zn^2+^ ([@bib55]) and have been shown to be required for catalysis in related proteins ([@bib55]; [@bib60]). We performed allele swapping at the L5 phage integrase site ([@bib52]) to replace the wild-type (WT) *cwlM* with the mutant allele *cwlM* E209A D331A. *cwlM* E209A D331A has zero out of four conserved Zn^2+^-coordinating residues, but is able to complement the WT allele in a growth curve assay ([Figure 1G](#fig1){ref-type="fig"}). Thus, CwlM is essential for cell survival and elongation in *Msmeg*, but its presumed amidase active site does not appear to be essential. CwlM may therefore have another function.

CwlM is phosphorylated, and this phosphorylation is important for cell growth {#s2-2}
-----------------------------------------------------------------------------

A proteomic screen in *Mtb* found that CwlM~TB~ is phosphorylated at T43 and T382 ([@bib56]). To determine whether the *Msmeg* CwlM is also phosphorylated, we constructed a strain with an epitope-tagged allele (*cwlM*::FLAG), immunoprecipitated the protein from *Msmeg* lysate and separated it with 2D gel electrophoresis. We found several CwlM species with different isoelectric points, a hallmark of phosphorylation ([Figure 2A](#fig2){ref-type="fig"}). Mass spectrometry of the gel spots identified phosphorylation at T35 and T374 (equivalent to T43 and T382 in the *Mtb* protein), as well as T376 and T378, and acetylation at K362 and K369. Most of the modifications are found at the C-terminal tail of the protein, which is highly conserved across actinomycetes ([Figure 2B](#fig2){ref-type="fig"}), despite being outside of a conserved domain. To assess whether phosphorylation is important for function, we replaced WT *cwlM* at the L5 site with mutants in which phosphorylated threonine residues were replaced by alanines. Most mutants grew normally but the L5::*cwlM* T374A strain grew slowly ([Figure 2C](#fig2){ref-type="fig"}; [Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}), despite containing normal amounts of CwlM protein ([Figure 2D](#fig2){ref-type="fig"}). The L5::*cwlM* T374A cells were short ([Figure 2E](#fig2){ref-type="fig"}) and defective for polar elongation ([Figure 2F](#fig2){ref-type="fig"}). Because the phenotypes of the L5::*cwlM* T374A strain are similar to the CwlM depletion ([Figure 1](#fig1){ref-type="fig"}), it seems likely that absence of phosphorylation on T374 inhibits the essential function of CwlM, though the T374A mutation could interrupt CwlM function in another way.10.7554/eLife.14590.005Figure 2.CwlM is phosphorylated and cytoplasmic.(**A**) 2-D gel of CwlM-FLAG from *Msmeg* (CB100) with the isoelectric point (pI) indicated on the bottom. (**B**) Weblogo diagrams of the C-terminus of CwlM homologues. Acetylation (Ac) and phosphorylation (PO~4~) sites are indicated. The colors of the three phosphates match the colors of the corresponding phospho-ablative strains in **C**, **E** and **F**. (**C**) Doubling times of L5::*cwlM*-FLAG WT (CB300) and phospho-ablative mutants (T374A = CB300; T376A = CB345; T378A = CB348). All multiple comparisons throughout were performed by One-way ANOVA with a Dunnett multiplicity correction. The adjusted p values for each mutant compared to WT are: T374A =\< 0.0001; T376A = 0.88; T378A = 0.15. (**D**) α-strep western blot of L5::*cwlM*-strep WT (CB663) and phospho-ablative mutants (CB666, 669, 672). A background band on the same blot probed with α-FLAG is used as a control. Westerns of the L5::*cwlM*-FLAG strains could not be used because of high background. (**E**) Cell length of 200--300 cells from L5::*cwlM*-FLAG WT and phospho-ablative mutants. The adjusted p values for each mutant compared to WT are: T374A =\< 0.0001; T376A = 0.99; T378A = 0.01. (**F**) Length of the longer unstained pole of cells in (**E**). Cells were stained with ARD and grown for three hours before imaging. The adjusted p values for each mutant compared to WT are: T374A =\< 0.0001; T376A = 0.59; T378A = 0.36. (**G**) Substituted cysteine accessibility. α-strep western of cells with strep-tagged Pgm (CB886, MSMEG_4579, cytoplasmic control), lprG (CB706, Rv1411, periplasmic control) and CwlM1cys (CB457) that were cysteine-blocked with MTSEA (membrane permeable) or MTSET (membrane impermeable) then alkylated at unblocked cysteines. Control samples: (−) = not alkylated or blocked, (+) = alkylated but not blocked. % alkylation (%alk.) = high band/ total for each sample. The periplasmic localization score = (%alk.~MTSEA~/% alk.~MTSET~) and is indicated below the gel for each protein ± the 95% confidence interval from two biological replicates. Scores \< 0.5 are cytoplasmic, near 1 are periplasmic.**DOI:** [http://dx.doi.org/10.7554/eLife.14590.005](10.7554/eLife.14590.005)10.7554/eLife.14590.006Figure 2---figure supplement 1.Growth rates of strains with different *cwlM* alleles.(**A**) Doubling times of ∆*cwlM Msmeg* strains with different *cwlM*-FLAG alleles at the L5 phage integrase site. WT = CB300; T35A = CB265; T374A = CB319; T376A = CB345; T378A = CB348; K362A = CB351; K369A = CB354. p values for each mutant against the WT were calculated with the students t test: all p values were insignificant except T374A \> 0.0001. (**B**) Doubling times of wild-type *M. smegmatis* mc^2^155 (CB1), mc^2^155 ∆*cwlM* L5::*cwlM*-FLAG (CB300) and mc^2^155 ∆*cwlM* L5::*cwlM* (CB236). p values: CB1 vs. CB300 \> 0.0001; CB300 vs. CB236 = 0.8. (**C**) Doubling times of mc^2^155 ∆*cwlM* L5::*cwlM*-strep (CB663) and mc^2^155 ∆*cwlM* L5::*cwlM* K362A K369A T376A T378A-strep (CB675), p value = 0.033.**DOI:** [http://dx.doi.org/10.7554/eLife.14590.006](10.7554/eLife.14590.006)

Peptidoglycan hydrolases and their direct regulators are found in the periplasm; however, CwlM lacks classical sec or tat secretion signal sequences ([@bib4]; [@bib53]). Moreover, phosphorylation of periplasmic proteins has not been described. To determine the compartmental location of CwlM, we used the Substituted Cysteine Accessibility Method (SCAM) ([@bib33]). We measured the accessibility of a cysteine on CwlM to agents with different membrane permeability and found that CwlM is only accessible to agents that can reach the cytoplasm ([Figure 2G](#fig2){ref-type="fig"}). Thus, CwlM is a cytoplasmic protein whose essential function is likely activated by phosphorylation.

CwlM is phosphorylated by PknB {#s2-3}
------------------------------

*Mtb* has 11 STPKs, which have been shown to phosphorylate many proteins involved in stress and growth ([@bib48]). To identify the cognate kinase of CwlM~TB~, we performed phospho-transfer profiling ([@bib3]) using proteins from the pathogen *Mtb,* which have high sequence conservation with the *Msmeg* homologues. We expressed and purified his-CwlM~TB~ and his-MBP (Maltose Binding Protein) fusions to the *Mtb* kinase domains (KD) of PknA, B, D, E, F, H, J, K and L, and measured phosphorylation of his-CwlM~TB~ using Western blotting with an α-phosphothreonine (α-thr\~P) antibody. We found that his-MBP-PknB~TB~(KD) phosphorylates his-CwlM~TB~ more rapidly than the other kinases ([Figure 3A](#fig3){ref-type="fig"}; [Figure 3---figure supplement 1A,B](#fig3s1){ref-type="fig"}). We used mass spectrometry to show that *in vitro*, his-MBP-PknB~TB~ phosphorylates his-CwlM~TB~ at threonines 382, 384 and 386 (equivalent to T374, 376 and 378 in *M. smegmatis*, [Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}). Thus, the phosphorylation sites in the C-terminal tail of CwlM are conserved in *Mtb* and *Msmeg*, which supports the idea that the strong sequence conservation of the CwlM C-terminal tail across actinomyecetes ([Figure 2B](#fig2){ref-type="fig"}) is functionally relevant.10.7554/eLife.14590.007Figure 3.CwlM is phosphorylated by PknB.(**A**) α-thr\~p western blots of *in vitro* kinase reactions with the kinase domains of 9 STPKs from *Mtb* fused to MBP and his-CwlM from *Mtb.* Reactions were stopped at 2 min. Longer time points are in [Figure 3-figure supplement 1B](#fig3s1){ref-type="fig"}. (**B**) α-thr\~p and α-FLAG western blot of lysates from a strain expressing CwlM-FLAG in a PknB~TB~ overexpression (CB418) background. PknB~TB~ was uninduced or induced for 30 min with 100 ng/ml Atc. Ratio = signal of (α-thr\~p / α-FLAG)~PknB\ OE~ / (α-thr\~p / α-FLAG)~uninduced~. Experiments in (**A**) and (**B**) were both performed twice, representative images are shown.**DOI:** [http://dx.doi.org/10.7554/eLife.14590.007](10.7554/eLife.14590.007)10.7554/eLife.14590.008Figure 3---figure supplement 1.Phosphorylation of CwlM.(**A**) α-phospho-threonine western blot of kinase reactions of the kinase domains (KD) of STPKs from *Mtb* fused to his-MBP incubated overnight at room temperature with his-GarA~TB~, a non-specific substrate. (**B**) α-phospho-threonine western blot of kinase reactions of his-CwlM~TB~ incubated with the kinase domains of STPKs from *Mtb* fused to his-MBP. (**C**) Alignment of CwlM from *Mtb* and *Msmeg*. Yellow boxes indicate the position of the PG binding 1 domains, green boxes indicate the position of the PG amidase domain. Residues highlighted in red were found to be phosphorylated in CwlM-FLAG pulled down from *Msmeg* cell lysates. Residues in orange were acetylated in these same lysates. Residues highlighted in blue were found to be phosphorylated on his-CwlM~TB~ expressed and purified from *E. coli* and incubated with his-MBP-PknB(KD)~TB~. All the modifications were identified by mass spectrometry.**DOI:** [http://dx.doi.org/10.7554/eLife.14590.008](10.7554/eLife.14590.008)

To test whether PknB affects CwlM phosphorylation *in vivo* we immunoprecipitated CwlM-FLAG from an *Msmeg* strain before and after induction of PknB~TB~ overexpression, and determined the degree of phosphorylation by comparing reactivity with α-thr\~P and α-FLAG antibodies ([Figure 3B](#fig3){ref-type="fig"}). We found that PknB~TB~ overexpression increases CwlM phosphorylation. Thus, PknB is likely the primary kinase of CwlM. This is consistent with the known essential role of PknB in phosphorylating proteins involved in cell growth and division ([@bib21]; [@bib32]). PknE may also contribute to CwlM phosphorylation.

CwlM interacts genetically and physically with MurA, a peptidoglycan precursor synthesis enzyme {#s2-4}
-----------------------------------------------------------------------------------------------

Phosphorylated CwlM appears to be required for normal cellular growth. To identify the molecular role of CwlM, we screened for spontaneous suppressor mutants that grow rapidly despite carrying only the growth-restrictive, phospho-ablative *cwlM* T374A allele. We passaged this strain until we isolated rapidly growing mutants, which were mapped using whole genome sequencing.

Three of five suppressor strains contained an identical S368P mutation in the gene *murA*. MurA is a cytoplasmic enzyme that catalyzes the first dedicated step in PG precursor synthesis: transfer of an enolpyruvyl group from phosphoenol pyruvate (PEP) onto UDP-N-acetylglucosamine (UDP-GlcNAc) ([@bib45]). The S368 residue is near the active site, according to an alignment with a structure of MurA from *L. monocytogenes* ([@bib25]) ([Figure 4A](#fig4){ref-type="fig"}).10.7554/eLife.14590.009Figure 4.CwlM binds to and regulates MurA.(**A**) Crystal structure of MurA from *L. monocytogenes* ([@bib25]). Orange: alanine that corresponds to S368 in *Msmeg* and *Mtb* MurA; gray: catalytic cysteine (aspartate in *Msmeg* and *Mtb.*). (**B**) Fitness of *cwlM* alleles in *murA* WT (CB737) and S368P (CB762) backgrounds, assessed by the percentage of colonies in which the WT *cwlM* allele was replaced by the indicated allele (WT = pCB277; T374A = pCB255; ∆CT = pCB557; ∆*cwlM *= pCB558). Four biological replicates of each transformation were performed, and 96--198 colonies were counted for each replicate. The Sidak correction for multiple comparisons was used to calculate p values using one-way ANOVA. The adjusted p values among the *murA* WT strains were calculated compared to *cwlM* WT: T374A =\< 0.0001; ∆CT =\< 0.0001; ∆*cwlM *=\< 0.0001. The adjusted p values among the *murA* S368P strains were calculated compared to *cwlM* WT: T374A = 0.99; ∆CT = 0.006; ∆*cwlM *=\< 0.0001. (**C**) α-FLAG and α-strep western blots of immunoprecipitates from the indicated strain (top three rows, from top: CB300, CB737, CB779) with the indicated antibody-conjugated beads (bottom two rows). The pulldown was performed twice, a representative image is shown.**DOI:** [http://dx.doi.org/10.7554/eLife.14590.009](10.7554/eLife.14590.009)10.7554/eLife.14590.010Figure 4---figure supplement 1.Growth rates of strains with different *cwlM* and *murA* regulatory alleles.Doubling times of strains. *cwlM* WT *murA* WT = CB779; *cwlM* WT *murA* S368P = CB782; *cwlM* T374A *murA* WT = CB319; *cwlM* T374A *murA* S368P = CB785. In the experiment described in [Figure 4](#fig4){ref-type="fig"}, we were not able to attain any *cwlM* T374A *murA* WT transformants, so the strain with this genotype is not isogenic with the other strains presented here. We were only able to attain colonies with the *cwlM* T374A *murA* WT genotype when the L5 allele swap was conducted in such a way that the correct swap was genetically forced. CB319 and the other strains presented in [Figure 2](#fig2){ref-type="fig"} were made by using a parental strain (CB233) in which the only copy of *cwlM* was under the control of an Atc-inducible promoter on an L5 vector that contained the *tetR* gene: this strain is Atc-dependent, because TetR will repress transcription of *cwlM* unless Atc is added. The alternate alleles of *cwlM* were under the control of Atc-inducible promoter on L5-integrating vectors that do not contain the *tetR* gene; they were transformed into CB233 and plated on plates that do not contain Atc. If the original L5 vector remains at the L5 site in addition to the new vector with the alternate allele, the TetR expressed from the original vector will repress transcription of both alleles of *cwlM* and cause cell death: thus, the loss of the original vector is forced, and we were able to recover colonies even with very slow growth rates. In the transformations described in [Figure 4](#fig4){ref-type="fig"}, resulting in strains CB779, 782 and 785, there was no *tetR* on either of the L5 vectors; thus, the swap was not forced, and at least half of the colonies from any transformation had both the original L5 vector with WT *cwlM* and the newly-transformed vector.**DOI:** [http://dx.doi.org/10.7554/eLife.14590.010](10.7554/eLife.14590.010)

To confirm that the *murA* S368P allele suppresses the growth defect of the *cwlM* T374A allele in a different genetic background, we performed L5 allele swapping of *cwlM* in strains encoding either WT *murA* or *murA* S368P. In these strains a WT allele of *cwlM* is encoded on an L5-integrated construct marked with the nourseothricin resistance gene. We transformed these cells with kanamycin-marked L5 vectors with alternate alleles of *cwlM.* Appropriate recombination can be scored by gain of the kanamycin marker and loss of the nourseothricin marker. We found that the *cwlM* T374A allele and a deletion of the C-terminal tail are poorly tolerated in a WT *murA* background, but can be recovered at near WT levels in a *murA* S368P background. The entire *cwlM* gene cannot be deleted in either background ([Figure 4B](#fig4){ref-type="fig"}). The strain carrying *murA* S368P alone grows at the same rate as WT, the strain with both mutant alleles has a slight growth defect, but grows much more rapidly than the strain with *cwlM* T374A and WT *murA* ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}).

These results confirm that *cwlM* and *murA* interact genetically. To test whether the proteins physically interact, we immunoprecipitated proteins from a strain containing *cwlM*-FLAG and *murA*-strep with both α-FLAG and α-strep beads. We found that CwlM-FLAG could be precipitated with α-strep beads, but only in the presence of MurA-strep, and vice versa ([Figure 4C](#fig4){ref-type="fig"}). Thus, there is a genetic link between *cwlM* and *murA,* and the two proteins interact.

CwlM∼P stimulates the enzymatic activity of MurA {#s2-5}
------------------------------------------------

We hypothesized that CwlM\~P activates MurA and that MurA is less active when CwlM is less phosphorylated, resulting in the inhibition of cell growth seen in the *cwlM* T374A mutant. This hypothesis is based on the observation that the phospho-ablated *cwlM* T374A is suppressed by *murA* S368P ([Figure 4B](#fig4){ref-type="fig"}), which is likely to be a gain-of-function mutation because *murA* is an essential gene ([@bib24]) and the mutation does not affect growth rate ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). To test this model we expressed and purified his-MurA~TB~ and his-CwlM~TB~ from *E. coli* and performed kinetic assays of his-MurA~TB~ activity by measuring the accumulation of the MurA product, enolpyruvyl-UDP-N-acetylglucosamine (EP-UDP-GlcNAc), by HPLC ([Figure 5A](#fig5){ref-type="fig"}). We compared the activity of his-MurA~TB~ alone and in the presence of his-CwlM~TB~ and his-CwlM~TB~\~P phosphorylated on T382, 384 and 386 by his-MBP-PknB~TB~ ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). We found that the reaction rate of his-MurA~TB~ is 20--40 times faster in the presence of equimolar his-CwlM~TB~\~P ([Figure 5](#fig5){ref-type="fig"}) than it is alone or with unphosphorylated his-CwlM~TB~. We found that nearly all his-CwlM~TB~ incubated with his-MBP-PknB~TB~ is phosphorylated on at least one site ([Figure 5---figure supplement 1F](#fig5s1){ref-type="fig"}); however, because there are three phosphorylation sites, it is likely a heterogeneous mixture. his-CwlM~TB~ with different degrees of phosphorylation may stimulate MurA activity differently, thus the rates in [Figure 5D](#fig5){ref-type="fig"} represent a population average of the rates from his-CwlM~TB ~in different states.10.7554/eLife.14590.011Figure 5.CwlM\~P activates MurA *in vitro*.(**A**) An HPLC trace from the MurA~TB~ kinetic assays, with substrate UDP-GlcNAc and product EP-UDP-GlcNAc indicated. Assays were done on his-MurA~TB~ alone, his-MurA~TB~ with equimolar his-CwlM~TB~\~P in an active kinase reaction (+ATP) with his-MBP-PknB~TB~(KD) (a his-Maltose binding protein fusion to the kinase domain (KD) of PknB from *Mtb*), or his-MurA~TB~ with his-CwlM~TB~ in an inactive kinase reaction (-ATP) with his-MBP-PknB~TB~(KD). (**B**) Rate of MurA activity vs. the concentration of phosphoenol pyruvate (PEP). Lines are the fit to the Michaelis Menten model. (**C**) Rate of MurA activity vs. the concentration of UDP-GlcNac for each MurA reaction condition. MurA and MurA+CwlM did not follow Michaelis Menten kinetics, (lines only connect the dots), for MurA+CwlM\~P the line is the Michaelis Menten fit. The assays shown in (**B**) and (**C**) were done twice with two separate preps of his-MurA~TB~ and his-CwlM~TB~. Data from one replicate is shown here, full data in [Figure 5 - figure supplement 1A--D](#fig5s1){ref-type="fig"}. (**D**) Michaelis Menten kinetic constants from experiments in (**B**) and (**C**). Constants are the average ± the 95% confidence interval from the two replicates. (**E**) Amount of EP-UDP-GlcNAc produced after 30 min at 37°C in reactions with 2 mM PEP and 15 mM UDP-GlcNAc and his-MurA~TB~ at 20 µg/ml; his-CwlM~TB~ at 20.2 µg/ml; his-MBP-PknB~TB~(KD) at 2 µg/ml and ATP at 1 mM where indicated. his-CwlM~TB~ was incubated with his-MBP-PknB~TB~ and ATP for 1 hr at RT before initiating the MurA reaction. T382A indicates that the singly-phosphoablative mutant protein his-CwlM~TB~ T382A was used. 3T-\>A indicates that the triply-phosphoablative mutant protein his-CwlM~TB~ T382A T384A T386A was used. Experiment was performed 2 times.**DOI:** [http://dx.doi.org/10.7554/eLife.14590.011](10.7554/eLife.14590.011)10.7554/eLife.14590.012Figure 5---figure supplement 1.MurA enzyme kinetics.Rates of MurA activity vs. \[PEP\] concentration with (**A**) the first preparation of his-MurA~TB~ and his-CwlM~TB~. (**B**) the second prep. Rates of MurA activity vs. \[UDP-GlcNAc\] concentration with (**C**) the first preparation of his-MurA~TB~ and his-CwlM~TB~ and (**D**) the second prep. Data in ABC and D were fit to the Michaelis Menten formula where possible, the lines indicate this fit. In C and D, the data for MurA alone and MurA +CwlM could not be fit to the Michaelis Menten formula. These reactions apparently operate under atypical kinetic parameters. (**E**) Concentration of EP-UDP-GlcNAc formed in a 30 min incubation at 37°C of 2 mM PEP, 15 mM UDP-GlcNAc, 20 µg/ml his-MurA~TB~ and his-CwlM~TB~\~P in an active kinase reaction at a range of CwlM:MurA molar ratios. (**F**) Two-dimensional gel of purified His-CwlM~TB~ after 1 hr incubation with his-MBP-PknB~TB~ in the absence (top) or presence (bottom) of ATP. The shift of the entire CwlM spot to a higher pI indicates that \~100% of the protein is phosphorylated.**DOI:** [http://dx.doi.org/10.7554/eLife.14590.012](10.7554/eLife.14590.012)

his-CwlM~TB~ with phosphoablative mutations does not appreciably stimulate his-MurA~TB~ activity after incubation with his-MBP-PknB~TB~ and ATP ([Figure 5E](#fig5){ref-type="fig"}). his-CwlM~TB~ alone cannot synthesize EP-UDP-GlcNAc; MurA is not thought to be phosphorylated ([@bib56]) and his-MBP-PknB~TB~ cannot stimulate MurA activity in the absence of his-CwlM~TB~ ([Figure 5E](#fig5){ref-type="fig"}). We measured the stoichiometry of the CwlM:MurA reaction and found that his-MurA~TB~ is maximally activated in a reaction with a 2-fold molar excess of fully phosphorylated his-CwlM~TB~\~P ([Figure 5---figure supplement 1E,F](#fig5s1){ref-type="fig"}). Thus, CwlM\~P activates MurA to initiate PG synthesis. These data with *Mtb* proteins confirm our model based on the genetic data in *Msmeg*, and show that CwlM~TB~\~P is a direct activator of MurA~TB~.

MurA activity is downregulated in the transition to starvation {#s2-6}
--------------------------------------------------------------

MurA from other species have been studied *in vitro* and shown to have much more rapid kinetics and lower K~m~ values than isolated MurA~TB~ ([Figure 5B,C](#fig5){ref-type="fig"}; [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}; [Supplementary file 1D](#SD1-data){ref-type="supplementary-material"} \[[@bib72]\]). Why would an essential housekeeping enzyme evolve to be almost inactive by default and require activation by another factor?

We hypothesized that this MurA regulatory pathway could exist to restrict PG synthesis in stresses such as nutrient starvation, because cell length decreases in starvation ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}) and when CwlM is deactivated ([Figures 1D, E](#fig1){ref-type="fig"}, [2E](#fig2){ref-type="fig"}). To test this, we immunoprecipitated CwlM-FLAG from *Msmeg* cultures in log phase and starvation and measured the degree of phosphorylation. We found that CwlM phosphorylation is quickly reduced upon starvation in PBS ([Figure 6A](#fig6){ref-type="fig"}).10.7554/eLife.14590.013Figure 6.MurA is downregulated in starvation, contributing to drug tolerance.(**A**) α-thr\~P western blot showing the level of CwlM phosphorylation in the *cwlM*::FLAG strain (CB100) in log. phase and upon starvation in PBS. Ratio = signal of (α-thr\~p / α-FLAG)~starvation~ / (α-thr\~p / α-FLAG)~log\ phase~(**B**) Amount of EP-UDP-GlcNAc produced after 30 min in a reaction with 20 µg/ml of his-MurA~MS~WT or his-MurA~MS~S368P, 2 mM PEP, 15 mM UDP-GlcNAc and either no or equimolar his-CwlM~TB~ or his-CwlM~TB~\~P. (**C**) Fluorescent intensity of WT (CB779) and *murA* S368P (CB782) cells pulse stained with TADA in log. phase HdB culture (t = 0) and at time points after initiation of starvation in PBS+tween 80, as measured by flow cytometry. The median fluorescence for 10K+ cells is shown. On the right are representative images of cells from the t = 0 (log. phase) and t = 24 (starved) time points. Phase and red fluorescent images of each are shown. The images were taken with identical exposure settings and the brightness and contrast was adjusted to identical levels. Pictures of several cells from images processed identically were pasted together. The scale bar applies to all the images. (**D**) Colony forming units per ml of strains with the *murA* WT (CB779) and S368P (CB782) alleles after transfer to PBS+tween80 starvation media and treatment with 100 µg/ml isoniazid, 20 µg/ml meropenem or 50 ug/ml rifampin. The p value for the indicated time point in each experiment was calculated by the student's t test. Isoniazid = 0.0087; meropenem = 0.0082; rifampin = 0.0067.**DOI:** [http://dx.doi.org/10.7554/eLife.14590.013](10.7554/eLife.14590.013)10.7554/eLife.14590.014Figure 6---figure supplement 1.Phenotypes of *murA* S368P.(**A**) Phase micrographs and quantification of *Msmeg* mc^2^155 (CB1) cell lengths in log. phase 7H9 and after 5 hr in HdB-C carbon starvation media. 500 cells from single cultures were measured for each condition. p\<0.0001 by the student's t test. (**B**). α-strep and α--Hsp65 western blots of A~280~-normalized lysates from *murA* WT (CB779) and S368P (CB782) cultures starved for four hours in Hdb-C. The *murA* allele in both these strains has a C-terminal strep tag. (**C**) Controls for flow cytometry. Cells were grown in HdB as in the t = 0 time point of [Figure 6C](#fig6){ref-type="fig"}, and either stained and then fixed as in [Figure 6C](#fig6){ref-type="fig"}, or fixed first and then stained, or fixed but not stained, and then subjected to flow cytometry. The median fluorescence for 10K+ cells is shown. (**D**) Fluorescence intensity of TADA stained *murA* WT and *murA* S368P cell fractions. Cells were extracted first with water and then SDS. The remaining cell wall pellets were photographed (inset), and all fractions measured by fluorimetry. Two replicates of each culture were used. (**E**) Colony forming units (CFU) of *murA* WT and S368P strains after being grown to log phase in 7H9, then pelleted and resuspended in PBS+tween80. (**F**) CFU of *murA* WT and S368P strains grown to log phase in 7H9 then treated with either 50 µg/ml isoniazid, 20 µg/ml rifampin or 5 µg/ml meropenem. (**G**) Colony forming units of *murA* WT and S368P strains after being grown to log phase in 7H9, then pelleted and resuspended in in PBS+tween80. At the 18 hr time point either 100 µg/ml isoniazid, 40 µg/ml rifampin or 20 µg/ml of meropenem was added. Error bars represent the standard deviation.**DOI:** [http://dx.doi.org/10.7554/eLife.14590.014](10.7554/eLife.14590.014)

These results, together with the biochemical data and the observation that MurA protein levels do not change substantially in starvation ([Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}), suggest that phosphorylation of CwlM converts MurA to an \'on\' state and that during starvation, decreased CwlM phosphorylation blocks further PG synthesis - because MurA alone or in the presence of unphosphorylated CwlM has very low activity ([Figure 5](#fig5){ref-type="fig"}). To assess the importance of this post-translational regulation of MurA on mycobacterial physiology, we further studied the *murA* S368P mutant.

The genetic data predict that *murA* S368P is active without CwlM phosphorylation. To test this, we expressed and purified his-MurA~MS~ WT and S368P and measured their activity alone and with his-CwlM~TB~ and his-CwlM~TB~\~P. We found that his-MurA~MS~S368P is more active than the WT protein in all conditions by about 2-fold ([Figure 6B](#fig6){ref-type="fig"}). This suggests that the mutant enzyme should produce more PG precursors than the WT strain, even in starvation. We assessed PG activity using a fluorescently labeled D-alanine analogue TAMRA-D-alanine (TADA), which is thought to be incorporated primarily into metabolically active PG ([@bib40]). We observed increased fluorescence in the strain carrying *murA* S368P as compared to the WT allele during the first 12 hr of PBS starvation, but, by 24 hr, the staining was equivalent between the strains ([Figure 6C](#fig6){ref-type="fig"}). Controls show that TADA staining is specific to the cell wall ([Figure 6---figure supplement 1C,D](#fig6s1){ref-type="fig"}). We interpret this to mean that post-translational regulation of MurA is important to control PG metabolism in logarithmic phase growth and during the transition to starvation, but that after prolonged starvation other regulatory mechanisms predominate to control PG metabolism. The abrupt cessation of growth ([Figure 6---figure supplement 1E](#fig6s1){ref-type="fig"}) and decreased CwlM phosphorylation ([Figure 6A](#fig6){ref-type="fig"}) imply that incorporation of new PG decreases upon starvation in the WT strain; however, TADA staining remains constant ([Figure 6C](#fig6){ref-type="fig"}). This suggests that TADA staining in these conditions may be due more to exchange of D-alanine in the periplasm by Ldts ([@bib12]) than to incorporation of new, labeled PG transported from the cytoplasm. Regardless, the over-activation of MurA clearly alters PG metabolism during the transition to starvation.

Regulation of PG biosynthesis contributes to antibiotic tolerance {#s2-7}
-----------------------------------------------------------------

Decreased synthesis of PG precursors and cell wall metabolism is an important adaptation to stress: subverting this regulation should be disadvantageous. Many models suggest that decreased metabolism contributes to Mtb's antibiotic tolerance during treatment. This is based on the observation that many antibiotics are less effective during starvation and stationary phase in Mtb ([@bib6]; [@bib27]; [@bib68]; [@bib71]) and other bacteria, likely because the activity of drug targets is reduced, or because permeability is decreased ([@bib34]; [@bib57]). We hypothesized that continued synthesis of PG during the transition to starvation could reduce antibiotic tolerance. To test this, we subjected cells to PBS starvation and measured antibiotic sensitivity in strains with *murA* WT and S368P alleles. We found a 3--100 fold increase in killing of the strain carrying the *murA* S368P allele when the strains were treated with isoniazid, meropenem or rifampin at the initiation of starvation ([Figure 6D](#fig6){ref-type="fig"}). The mutant also had a significant antibiotic tolerance defect in nutrient rich media, but not when the antibiotics were added late in starvation ([Figure 6---figure supplement 1F,G](#fig6s1){ref-type="fig"}), after the period in which post-translational regulation of MurA affects PG metabolism ([Figure 6C](#fig6){ref-type="fig"}). We conclude that the PknB-CwlM-MurA signaling cascade functions to quickly turn off PG synthesis during nutrient restriction ([Figure 7](#fig7){ref-type="fig"}), and that this regulation contributes to antibiotic tolerance during growth and under changing conditions.10.7554/eLife.14590.015Figure 7.Phylogenetics and model for the PknB-CwlM-MurA regulatory pathway.(**A**) Domain structure of CwlM from mycobacteria. (**B**) Phylogenetic analysis of *cwlM* in the actinobacteria. Tree is based on a 16S rRNA alignment for each species. Species indicated in gray do not contain *cwlM* homologues, and are representatives of larger clades. All homologues lack a predicted secretion signal. The conservation of an intact or degenerate amidase active site and the presence of a PTG or TGT phosphorylation motif are indicated by color. (**C**) Model for the regulation of MurA. In nutrient rich conditions PknB phosphorylates CwlM, which can then promote the activity of MurA, resulting in increased flux through the PG biosynthetic pathway (indicated by the series of arrows) and promoting cell growth. In starvation, PknB is poorly expressed, CwlM is not phosphorylated, and MurA is therefore not activated, resulting in reduced production of PG precursors, which helps to halt cell growth.**DOI:** [http://dx.doi.org/10.7554/eLife.14590.015](10.7554/eLife.14590.015)

CwlM protein evolution was driven by cytoplasmic localization {#s2-8}
-------------------------------------------------------------

CwlM's function could not have been predicted from available knowledge about the function of its conserved domains. Based on domain structure, it seems likely that an ancestral *cwlM* homologue was a periplasmic enzyme involved in PG hydrolysis. How could such a protein evolve into a cytoplasmic, phosphorylation-responsive regulator of PG biosynthesis? To address this, we searched for *cwlM* homologues that retained both PG binding domains and the PG amidase domain in the same arrangement as is seen in the mycobacterial proteins ([Figure 7A](#fig7){ref-type="fig"}), and found that almost all such homologues were found in members of the phylum Actinobacteria. We chose representatives from each family and searched for the presence of a secretion signal, the conservation of the four Zn^2+^-coordinating residues, and the presence of a PTG or TGT phosphorylation motif in the C-terminal tail. We constructed a phylogenetic tree based on 16S rRNA sequence of the species that have *cwlM* homologues and some representative species from families that do not, and mapped onto it the conservation of the three *cwlM* features ([Figure 7B](#fig7){ref-type="fig"}). We found that all actinobacterial *cwlM* homologues lack secretion signals. Potential phosphorylation motifs are conserved in most clades, irrespective of whether or not they conserve the canonical Zn^2^+-coordinating residues. These data imply that both CwlM cytoplasmic localization and, possibly, regulation by phosphorylation were present in an ancestor of the Actinobacteria.

Discussion {#s3}
==========

Here we describe a regulatory system in which the essential STPK PknB phosphorylates the cytoplasmic PG amidase homologue CwlM, which then directly activates the catalytic activity of MurA, the first enzyme in the pathway of PG biosynthesis. During starvation, phosphorylation of CwlM is rapidly reduced, which leads to MurA deactivation and helps control PG metabolism at the cell wall. When this regulatory pathway is subverted by over-activation of MurA in *Msmeg*, cells become more sensitive to antibiotics.

CwlM has a critical role in signal transduction {#s3-1}
-----------------------------------------------

CwlM is essential in *M. smegmatis*, but its amidase activity does not appear to be essential ([Figure 1](#fig1){ref-type="fig"}). However, a strain with a phospho-ablative mutation, *cwlM* T374A, exhibits defects in elongation ([Figure 2](#fig2){ref-type="fig"}) and reduced viability in a manner reminiscent of CwlM depletion. The *cwlM* T374A mutant strain has such low viability that it could not be constructed except in a genetic background that 'forced' the L5 allele swap by repressing transcription of *cwlM* in transformants that maintained a wild type copy of the *cwlM* allele (See [Figure 2](#fig2){ref-type="fig"} and [4B](#fig4){ref-type="fig"} ; [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"};[Supplementary file 1](#SD1-data){ref-type="supplementary-material"} ). We show that the *murA* S368P mutation restores normal growth of the *cwlM* T374A mutant ([Figure 4B](#fig4){ref-type="fig"}; [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}) which implies that phosphorylation of CwlM activates MurA. The short cells seen in the CwlM depletion and the *cwlM* T374A mutant look similar to *Msmeg* cells with a temperature sensitive MurA mutation, which are also short and have compromised cell walls ([@bib72]).

The loss of viability in the *cwlM* mutants and temperature sensitive *murA* strain ([@bib72]) could be due to uncoordinated synthesis of the various layers of the cell wall: peptidoglycan biosynthesis is downregulated but other cell wall biosynthetic and metabolic processes may remain active, leading to a cell wall with poor structural integrity. This differs from wild-type regulation during starvation, when PG regulation is likely accompanied by regulation of other cell wall layers. In fact, PknB, the kinase likely responsible for physiologic CwlM phosphorylation, has been implicated in the regulation of many cell wall processes ([@bib35]; [@bib47]; [@bib50]; [@bib67]), and probably helps to coordinate regulation of the various cell wall layers. The enzymatic activity of other PknB substrates changes less upon phosphorylation ([@bib35]; [@bib47]; [@bib50]) than the \~30-fold activation of MurA by CwlM\~P. It is possible that PknB may regulate other factors like it does MurA -- indirectly through intermediary substrates.

CwlM may integrate information from multiple signals {#s3-2}
----------------------------------------------------

Both PknB and PknE can phosphorylate CwlM *in vitro*. Because PknB acts more rapidly ([Figure 3A](#fig3){ref-type="fig"}) it is likely to be the primary kinase of CwlM. In nutrient replete conditions PknB apparently activates MurA by phosphorylating CwlM. How is the phosphorylation cascade regulated in starvation? PknB can be transcriptionally ([@bib32]) and post-translationally regulated ([@bib3]). However, the rapid decrease in CwlM phosphorylation ([Figure 6B](#fig6){ref-type="fig"}) implies that there is a CwlM phosphatase.

CwlM is a cytoplasmic PG hydrolase homologue. While most PG hydrolases are in the periplasm, there are cytoplasmic PG hydrolases that are involved in enzymatic processing of recycled anhydro-muropeptides ([@bib29]; [@bib30]; [@bib51]). The level of cytoplasmic anhydro-muropeptides can be a signal reporting on environmental conditions ([@bib29]; [@bib30]; [@bib51][@bib49]). If CwlM is involved in processing or detection of anhydro-muropeptides, it could integrate information about their levels into its regulation of PG precursor synthesis.

Regulation of MurA toggles PG biosynthesis in response to prevailing conditions {#s3-3}
-------------------------------------------------------------------------------

Because MurA is the first committed step in PG biosynthesis, its regulation is an efficient point at which to regulate the pathway. This is certainly true in other species. MurA from *E. coli* is subject to feedback regulation ([@bib46]), and many Gram positive species have two MurA homologues which are differentially regulated ([@bib8]; [@bib38]). Mycobacteria have only one MurA homologue, but the regulation by CwlM allows it to quickly and precisely adjust its enzymatic activity for different conditions without being proteolyzed and requiring re-synthesis ([Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}). Our data imply that the post-translational regulation of MurA is important for cell wall regulation at early time points during stress ([Figure 6C](#fig6){ref-type="fig"}). It is likely that transcriptional ([@bib15]) and proteolytic ([@bib22]) systems downregulate cell wall enzymes after prolonged starvation or stress.

The K~cat~ values we measured for MurA alone by varying PEP concentration are comparable to the values measured previously ([@bib72]), and the K~cat~ of MurA with CwlM\~P was \~30 times higher. We and others have measured high K~m~ values for UDP-GlcNAc ([Figure 5D](#fig5){ref-type="fig"}; [Supplementary file 1D](#SD1-data){ref-type="supplementary-material"}; [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"} and \[[@bib72]\]), which surely exceed the concentrations in the cell; thus, there are probably other factors that regulate MurA and either reduce the K~m~ or increase the local concentration of UDP-GlcNAc.

A regulatory system for PG biosynthesis contributes to drug tolerance {#s3-4}
---------------------------------------------------------------------

One of the major limitations in treating tuberculosis is the extended course of therapy required in part because of phenotypic drug tolerance, which is thought to be a result of decreased metabolic activity of drug targets, and decreased permeability. Subverting signals that downregulate metabolism in these bacteria could re-sensitize them to antibiotics. We find that this is true during the transition to starvation in *Msmeg* grown in culture. A strain carrying the *murA* S368P allele is unable to properly downregulate PG metabolism, and is more sensitive to several antibiotics early in starvation ([Figure 6D](#fig6){ref-type="fig"}). Because this increased killing was seen in the presence of isoniazid and meropenem, which target the cell wall, as well as rifampin, which does not, we think that the increased cell wall metabolism results in higher permeability, and that the increased killing is due to greater drug uptake ([@bib57]).

Our data imply that MurA inhibitors ([@bib17]) might contribute to death of actively growing mycobacteria early in treatment, but that they could also contribute to drug tolerance of non-growing bacteria, which are likely to dominate later in treatment. While our experiments were conducted *in vitro* with *Mtb* proteins, the conservation of these proteins among mycobacteria suggest that the PknB-CwlM-MurA regulatory pathway is conserved, although it is likely that different stresses activate MurA regulation in *Mtb* compared to *Msmeg*. Treatments that interfere with the regulation of the mycobacterial cell wall during infection could shorten treatment times and improve patient outcomes.

The evolution of CwlM function {#s3-5}
------------------------------

Biological complexity is predicated on the diversity of protein function. How do novel protein functions evolve? One hypothesis is that compartmental re-targeting of duplicated genes is critical to the evolution of complexity in eukaryotic cells ([@bib9]; [@bib23]). It is less clear that this same mechanism would drive the evolution of complexity in bacteria.

Here, though, we find a bacterial example of evolutionary repurposing through new compartmentalization. Because CwlM consists of three functional domains, all of which are predicted to function in the periplasm, we assume that an ancestral homologue was periplasmic. However, all of the available *cwlM* homologues lack a predicted secretion signal. These homologues are found throughout the Actinobacteria, implying that a *cwlM* ancestral homologue was re-targeted to the cytoplasm before the actinobacterial phylum split off from its relatives. The conservation of the putative phosphorylation motif implies that *cwlM* homologues in most Actinobacteria have a role in signal transduction. Because periplasmic proteins are not known to be phosphorylated, this signaling role likely evolved after CwlM was re-targeted to the cytoplasm.

CwlM provides cells with an additional layer of regulation of PG synthesis. MurA from Gram negative ([@bib16]; [@bib39]) and positive species ([@bib8]; [@bib20]) are regulated transcriptionally and by proteolysis ([@bib8]; [@bib38]). In mycobacteria, enzymes in PG biosynthesis are regulated transcriptionally ([@bib15]) and proteolytically ([@bib22]), in addition to the regulation of MurA through phosphorylation of CwlM described here. Thus, compartmental re-targeting of the ancestral CwlM protein has allowed for the evolution of a complex regulatory system by which mycobacteria, and possibly related Actinobacteria, control synthesis of PG precursors in response to environmental conditions.

Materials and methods {#s4}
=====================

Bacterial strains and culture conditions {#s4-1}
----------------------------------------

*Mycobacterium smegmatis* mc^2^155 was grown in 7H9 salts (Becton-Dickinson, Franklin Lakes, NJ) supplemented with: 5 g/L albumin, 2 g/L dextrose, 0.85 g/L NaCl, 0.003 g/L catalase, 0.2% glycerol and 0.05% Tween80, or plated on LB agar. Hartmans-de Bont (HdB) media was made as described ([@bib26]) with 0.05% tween80, HdB-C was made without glycerol. *E. coli* DH5α was used for cloning and *E. coli* BL21 codon plus or ArcticExpress DE3 RP were used for protein expression. Antibiotic concentrations for *M. smegmatis* were: 25 µg/ml kanamycin, 50 µg/ml hygromycin, 20 µg/ml zeocin and 20 µg/ml nourseothricin. Antibiotic concentrations of *E. coli* were: 50 µg/ml kanamycin, 100 µg/ml hygromycin, 25 µg/ml zeocin, 40 µg/ml nourseothricin, 20 µg/ml chloramphenicol and 140 µg/ml ampicillin. All strains were grown at 37°C.

Strain construction {#s4-2}
-------------------

Knockouts of *cwlM* and *murA* were made by first complementing the genes at the phage integrase sites L5 ([@bib44]) and Tweety ([@bib54]), and then using recombineering to delete the endogenous copy. \~500 base pair regions upstream and downstream of the gene were amplified by PCR and PCR stitched to either side of a zeocin resistance cassette. The assembled PCR fragment was transformed into *Msmeg* strains expressing the RecET proteins. The resulting colonies were screened for deletion of the gene ([@bib66]). To make CB737, the zeocin resistance cassette in the deletions was removed by the Cre recombinase between each subsequent deletion. After complementing *murA* at the Tweety site and deleting the endogenous *murA*, we found that there was still another copy of *murA* in its native genomic context. This led to our discovery of an IS1096-mediated ([@bib69]) genomic duplication which comprises MSMEG_4928--4944 (*murA* is MSMEG_4932) and is present in most of our *Msmeg* strains. We deleted the second copy of *murA* by removing the zeocin cassette in the first deletion via Cre recombinase, and using the same knockout construct to delete the second copy.

The *cwlM*::FLAG (CB100) strain was also made by recombineering. \~500 base pair regions upstream and downstream of the stop codon of *cwlM* were amplified and PCR stitched to a zeocin cassette, which was transformed as described above.

Different alleles of *cwlM* were attained by swapping the nourseothricin resistance-marked vector with WT *cwlM* for a kanamycin resistance-marked mutant allele, as described ([@bib52]). We also exchanged the *murA* allele at the Tweety integrase site in the same way as is done at the L5 site. Full strain details in [Supplementary file 1A--C](#SD1-data){ref-type="supplementary-material"}.

Cell staining, microscopy and image analysis {#s4-3}
--------------------------------------------

For polar growth quantification, cells were stained with AlexaFluor488 carboxylic acid succinimidyl ester as described ([@bib2]), resuspended in 7H9 media, shook at 37°C for 3 hr, immobilized on agarose pads and imaged in phase and GFP channels with a Nikon TE-200E microscope with a 60X objective and Orca-II CCD camera (Hamamatsu, Japan). The Ptet::*cwlM* strain was grown uninduced for 9 hr before staining. Images were analyzed in ImageJ (NIH). The length of the longer unstained pole and the total cell length was measured manually for each cell.

D-alanine staining and flow cytometry {#s4-4}
-------------------------------------

For the TADA experiment, cells were grown in HdB. 1 µl of 10 mM TADA (synthesized according to \[[@bib41]\]) was added to 1 mL of culture and incubated for 5 min before washing with PBS+tween80 and fixing for 10 min with 1% paraformaldehyde. The rest of the culture was pelleted, resuspended and cultured in PBS+tween80, and aliquots were stained the same way at 1, 4, 8, 12 and 24 hr after resuspension. Controls were performed on cells growing in HdB: cells were either fixed first and then stained, or fixed and not stained at all. The samples were filtered through a 10 µm filter and analyzed by flow cytometry (MACSQuant VYB Excitation: 561 nm; Emission filter: 615/20). The settings for FSC, SSC, and cell density were adjusted to sample single cells. Three biological replicates were used for each strain and time point, and the median fluorescence for 50,000 cells from each replicate was calculated and averaged.

D-alanine staining and cell fractionation {#s4-5}
-----------------------------------------

75 mL replicate cultures of *murA* WT and *murA* S368P growing in HdB were stained for 15 min at 37**°C** with 10 µM TADA. Cells were pelleted and washed twice with PBS+tween80, resuspended in water and boiled for 1 hr, and spun at 100 K rpm for 20 min. The supernatants were collected, and the pellets resuspended in PBS+2.5% SDS, boiled for 1 hr, nutated O/N at 37°C, and spun at 21 K rpm for 15 min. The supernatants were collected and the pellets were washed twice with PBS. The fluorescence of each sample was measured with a Spectra284 plate reader (Excitation: 541, Emission: 568). The water and SDS extracted supernatants were measured undiluted. The cell wall pellet suspension was diluted 120 fold, which was required for measurements to be within the linear range. The fluorescence values of the cell wall fractions measured by the plate reader were therefore multiplied by 120.

Protein purification and phospho-transfer profiling {#s4-6}
---------------------------------------------------

N-terminally his-MBP-tagged kinase domains of the nine canonical serine-threonine protein kinases from Mtb were expressed and purified as described ([@bib36]). His-CwlM was expressed with 1 mM IPTG at 14° for 40 hr in ArcticExpress DE3 RP (Agilent, Lexington, MA). Cells were resuspended and French-pressed in Ni Wash Buffer (50 mM NaHPO~4~ pH 8.0, 300 mM NaCl, 20 mM imidazole), and supernatants were poured over TALON affinity resin (Clontech, Mountain View, CA). Bound proteins were washed and eluted with Ni Wash Buffer + 200 mM imidazole. Soluble proteins were separated from aggregates on a Superdex S200 gel filtration column (GE Healthcare, Westborough, MA) in 20 mM Tris pH 7.5, 150 mM NaCl, 1 mM DTT. Soluble proteins were concentrated and stored in 50 mM NaPO~4~ pH 7.5, 150 mM NaCl, 20% glycerol, 2 mM DTT, 1 mM PMSF. Kinase reactions, α-phospho-threonine western blots and mass spectrometry were performed as described ([@bib36]).

Growth rate determination {#s4-7}
-------------------------

Growth curves of *M. smegmatis* strains were done in triplicate, the OD~600~ of each culture was measured every 30 min in a Bioscreen growth curve machine (Growth Curves USA, Piscataway, NJ).

Conservation of C-terminal tail {#s4-8}
-------------------------------

To determine the conserved features of the C-terminus of CwlM, the entire CwlM protein sequence was BLASTed against the genus Mycobacteria, and the C-terminal tail from the 34 most similar mycobacterial, and 98 most similar Actinomycetes CwlM proteins was analyzed using Weblogo ([@bib13]).

2D gels, SDS-PAGE and western blots {#s4-9}
-----------------------------------

For 2D gels and phosphothreonine quantification of CwlM, CwlM-FLAG was immunoprecipitated by bead beating cells in 50 mM Tris pH7.5, 300 mM NaCl with Protease Inhibitor Cocktail (Roche, Switzerland). α-FLAG M2 Magnetic Beads (Sigma Aldrich, Natick, MA) were added to supernatants and washed with 50 mM NaHPO~4,~ 300 mM NaCl. CwlM was eluted from the beads with 0.5 mg/ml FLAG peptide in TBS. Samples were separated in 2D using the ReadyPrep 2D Starter Kit (BioRad, Hercules, CA), according to the manufacturer's protocols. SDS-PAGE was done with 4--12% NuPAGE Bis Tris precast gels (Life Technologies, Beverley, MA). Mouse α-FLAG (Sigma Aldrich) was used at 1:10,000 in TTBS, Rabbit α-strep (Genscript, China) and Rabbit α-phosphothreonine (Cell Signaling Technology, Danvers, MA) were used at 1:1000 in TTBS + 0.5% BSA.

Substituted cysteine accessibility {#s4-10}
----------------------------------

Cultures of the L5::*cwlM*1cys-strep, L5::*lprG*-strepC and L5::*pgm*-strepC strains were grown to late log phase, washed twice and resuspended in PBS + 0.25% tween80, split and treated with 0 or 0.6 mg/ml of MTSEA and MTSET (Biotium, Hayward, CA) for 20 min at RT. Blocking was quenched with cysteine at 50 mM; cells washed in PBS + 0.05% tween80, and resuspended in PEGylation buffer (600 mM Tris pH 7.4, 10 M Urea, 2% SDS, 1 mM EDTA), heated at 85° for 20 min and spun. 5.6 mg of MalPEG5K (Sigma Aldrich) was added to all the supernatants except (-) controls and incubated at 37° for 2 hr. Proteins were TCA precipitated and visualized by α-strep western blot.

Cwl*M* allele survivability {#s4-11}
---------------------------

To confirm the suppression of the *cwlM* T374A allele by the *murA* S368P allele, the L5::*cwlM*(nuoR) tw::*murA* (CB737) and L5::*cwlM*(nuoR) tw::*murA* S368P (CB762) strains were transformed with pCB255, pCB277, pCB557 and pCB558 and plated on kanamycin. For each of 3--4 transformations, kanamycin and nourseothricin resistance was assessed for 96-192 colonies.

CwlM-MurA co-immunoprecipitation {#s4-12}
--------------------------------

Cultures of CB779, CB737 and CB300 were grown to mid-log phase, washed, resuspended in PBS + 0.25% paraformaldehyde, incubated at 37° for 2 hr, quenched with 40 mM glycine, washed and lysed by French press. α-strep was conjugated to Protein G dynabeads (Novex, Cambridge, MA) which were added to the CB300 and the CB779 lysate. α-FLAG beads were added to the rest of the CB779 lysate and the CB737 lysate. Pull-downs were done according to the manufacturers protocols, and proteins visualized by western blot.

MurA kinetic assays {#s4-13}
-------------------

his-MurA was purified like his-CwlM. Reactions with 20 µg/ml of his-MurA, equimolar his-CwlM in the kinase reaction, and varying concentrations of substrate were run as in ([@bib10]). MurA kinetic assays were done with MurA~TB~ alone in MurA reaction buffer (50 mM Tris pH 8.0, 2 mM Kcl, 2 mM DTT) or with equimolar CwlM~TB~ in a kinase reaction with His-MBP-PknB~KD~. The kinase reactions contained: 202 µg/ml CwlM~TB~, 50 µg/ml His-MBP-PknB~KD~, 2 mM ATP, 2 mM MnCl~2~ and were brought up to 100 µl with Buffer C (20 mM Tris pH 7.5, 150 mM NaCl, 1 mM DTT). Inactive kinase reactions had extra buffer instead of ATP. Kinase reactions were run for 1 hr at room temperature before being added to the MurA reactions. MurA reactions contained: 20 µg/ml MurA and 20.2 µg/ml CwlM in the kinase reaction (1/10 of MurA reaction was CwlM kinase reaction, or buffer for MurA alone kinetics). In MurA reactions with varying PEP, UDP-GlcNac was at 10 mM and PEP concentrations were: 25, 100, 250, 500 and 1000 µM; these reactions were started with the addition of UDP-GlcNAc. In MurA reaction with varying UDP-GlcNac, PEP was at 2 mM and UDP GlcNac concentrations were: 0.5, 1, 3, 5, 8, 10 and 15 mM; these reactions were started with the addition of PEP. 2, 5 and 8 min time points were taken for the MurA + CwlM\~P reaction; 5, 15 and 25 min time points were taken for the MurA and MurA +CwlM reactions. At the indicated time point, a 25 µl aliquot of the reaction was removed and quenched in an equal volume of 400 mM KOH. The quenched reactions were spun in Microcon 10 K devices (EMD Millipore, Billerica, MA) and chilled until being injected into the Agilent HPLC. HPLC separation was performed on a MonoQ 5/50 GL anion exchange column (GE Healthcare) with the following protocol: 0.6 ml/min; 2 min of 20 mM tetraethylammonium bicarbonate pH 8.0, an 18 min gradient from 20--500 mM tetraethylammonium bicarbonate pH 8.0, 5 min of 500 mM tetraethylammonium bicarbonate pH 8.0, 5 min of 20 mM tetraethylammonium bicarbonate pH 8.0. The area under the A~254~ curve peak corresponding to EP-UDP-GlcNAc was integrated using Agilent ChemStation software.

Because EP-UDP-GlcNac is not commercially available, we were not able to perform a standard curve of product concentrations to determine the relationship between peak area and product concentration. Instead, we measured the peak area of a range of UDP-GlcNac concentrations, and found that a peak area of 11.73 in the A~254~ curve was consistently equivalent to 1 uM of UDP-GlcNac. Because UDP-GlcNac and EP-UDP-GlcNac differ only in one enol-pyruvyl group, we reasoned that the relationship between A~254~ peak area and concentration should be comparable between these two molecules. We therefore divided the values for peak area for each EP-UDP-GlcNac peak by 11.73 to calculate the approximate µM concentration of EP-UDP-GlcNac. These values were plotted vs. time for each substrate concentration and the rate of product produced vs. time was calculated based on the linear portions of the curves. The resulting rates were plotted against substrate concentration in the curves shown in [Figure 5](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}. The peak that corresponds to EP-UDP-GlcNAc was identified because it appeared only when MurA and UDP-GlcNAc were incubated with PEP. The data were fitted to the Michaelis Menten formula using GraphPad Prism.

Antibiotic kill curves {#s4-14}
----------------------

Biological replicates of CB779 (*murA*) and CB782 (*murA* S368P) were grown in 7H9, transferred to PBS+tween80, diluted to OD = 0.05, treated with 100 µg/ml isoniazid, 50 µg/ml rifampin or 20 µg/ml meropenem, and rolled at 37° during the CFU measurement period. For the unstarved kill curves ([Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}), log. phase cultures in 7H9 were diluted to OD = 0.05 in 7H9 and treated with 50 µg/ml isoniazid, 20 µg/ml rifampin or 5 µg/ml meropenem. For [Figure 6---figure supplement 1D](#fig6s1){ref-type="fig"}, the log. phase 7H9 cultures were transferred to PBS+tween80, diluted to OD = 0.05 and rolled at 37° for 18 hr before 100 µg/ml isoniazid, 50 µg/ml rifampin or 20 µg/ml meropenem was added.

CwlM feature conservation analysis {#s4-15}
----------------------------------

A CDART search was used to identify *cwlM* homologues with the same domain structure. All but 3 of these were in the Actinobacteria, the remaining 3 are in the Firmicutes. The \~700 CDART hits were separated by family, and a phylogenetic tree was made of each family. Between 3 and 16 homologues, representing the breadth of the phylogenetic distribution, were chosen from each family, leaving 97 homologues. The secretion signal identification programs Phobius ([@bib31]) and PRED-TAT ([@bib4]) were used to assess the N-terminus of each homologue for the presence of a Sec or Tat secretion signal. The COBALT tool on NCBI was used to align the amidase domain of each homologue to active amidase domains of the same family; the conservation of the four Zn^+2^-coordinating residues was assessed for each. Each homologue was then searched for the presence of either PTG or TGT motifs in the C-terminal region after the amidase domain. 16S rRNA sequences were collected from the species with the 97 CwlM homologues, and from representative species from across the clade of Actinobacteria ([@bib42]) that do not have CwlM homologues. The 16S sequences were aligned with Clustal Omega and a distance-matrix tree was constructed and visualized in ITOL ([@bib43]).
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your work entitled \"A cytoplasmic peptidoglycan amidase homologue controls mycobacterial cell wall synthesis\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Detlef Weigel as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The reviewers liked several aspects of the work and found a possible role of CwlM as a cytoplasmic regulator of MurA in mycobacteria intriguing. However, there were also a number of concerns raised about the completeness and rigor of many of the experiments presented. The collective comments of the reviewers have been merged and are listed below in two categories, Essential Revisions and Minor Points. As you will see, the Essential Revisions include a number of cases where additional experiments will be required. If you feel that each of the items below can be fully addressed, we would encourage you to submit a revised manuscript that would then be re-reviewed.

Essential revisions:

1\) The claim that CwlM is non-enzymatic is not sufficiently rigorous. It is true that mutations in putative catalytic residues do not cause a loss of function, but this is rather weak; they need to show explicitly that the mutant protein is inactive biochemically. In addition, the mutagenesis is based on the analysis of a truncated *B. subtilis* protein and the paper cited describes numerous mutations not in the catalytic residues that also inactivated the protein. So, the linkage between specific mutations and lack of catalysis is tenuous. Additionally, according to Deng et al. it does have activity -- do you not agree and if so, why?

2\) [Figure 1B](#fig1){ref-type="fig"}: why does depleting CwlM cause cells to die rather than just stop growing? If the model is that CwlM is simply required for promoting cell elongation, then why don\'t cells lacking CwlM just stop growing? As shown later, when CwlM phosphorylation is downregulated in starvation conditions, cells stop growing, but presumably are not dying, so reconciling these data is important. [Figure 1D](#fig1){ref-type="fig"}: Do CwlM-depleted cells phenocopy MurA-depleted cells (Xu et al., 2014) or show any shape changes or lysis?

3\) Does the T374A mutant lose viability like the depletion strain? The doubling time is longer ([Figure 2C](#fig2){ref-type="fig"}) and the cells don\'t grow polarly ([Figure 2F](#fig2){ref-type="fig"}) but what about viability?

4\) The authors cite Kall et al. 2007 as evidence that CwlM lacks a secretion signal, but that paper is only a citation to a prediction server and furthermore, running CwlM through that server yields the prediction of a non-cytoplasmic (i.e., secreted) protein. The determination of compartmental localization using the MTSEA/MTSET is also confusing and should be clarified. The authors state in the legend to [Figure 2](#fig2){ref-type="fig"} that \"scores \>1 are periplasmic, \<1 are cytoplasmic\", so why does mRFP, unambiguously a cytoplasmic protein, have a value of.84 ±. 40. In addition to a better explanation of the MTSEA/MTSET approach, the authors should consider a more traditional approach, such as fractionation, unless it is experimentally too demanding. And, perhaps more importantly, is it possible that some CwlM is present in each compartment? Unless this can be categorically ruled out, the authors should adjust their language about the cellular location of CwlM throughout the paper, including in the title.

5\) T374 is phosphorylated and the T374A mutant displays some of the phenotypes associated with a *cwlM* depletion strain. But formally such data alone do not support the conclusion that \"CwlM is a cytoplasmic protein whose essential function is activated by phosphorylation.\" It could be well be that the threonine at position 374 is important for its essential function but not because it must be phosphorylated. At a bare minimum, the authors need to be more precise in their language. Preferably, they would address this experimentally -- for example, by testing whether a phosphomimetic (T374D or T374E) allele is hyperactive with respect to activating MurA -- has this been tried?

6\) Do constitutively active forms of CwlM rescue the essentiality of *pknB* mutants? And does the S368P mutation in *murA* bypass essentiality of *pknB*?

7\) [Figure 5](#fig5){ref-type="fig"}: The activation of MurA by CwlM+PknB is convincing, although the authors need to also show that MurA is not activated by CwlM(T347A)+PknB to ensure that PknB isn\'t having some other effect independent of T347 phosphorylation. Also, does CwlM(T347A) no longer activate MurA, as predicted from the genetics? Finally, is the basal level activity of the Mtb version of MurA(S368P) significantly higher than that of wt MurA, and/or is unphosphorylated CwlM sufficient to stimulate its activity?

8\) In the experiment in [Figure 5](#fig5){ref-type="fig"} showing the effect of phosphorylation on the ability of CwlM to activate MurA, they need to characterize the stoichiometry of phosphorylation -- the data indicate that this is quite high, but that would be the exception for bacterial phosphoproteins. Also, as noted above, they should try the phosphomimetic mutant of T374 to confirm the genetic data from [Figure 2E](#fig2){ref-type="fig"}.

9\) [Figure 6B](#fig6){ref-type="fig"} suggests that the change in CwlM phosphorylation is because of a change in PknB levels, but the authors need to verify this by showing that constitutive expression of PknB maintains CwlM phosphorylation upon starvation.

10\) [Figure 6C, D](#fig6){ref-type="fig"}, subsection "MurA activity is downregulated in starvation" -- The TADA incorporation experiments ([Figure 6C](#fig6){ref-type="fig"}) suggest that the *murA*(S368P) cells still produce PG upon starvation when the wt cells do not (so much). The authors suggest that growth inhibitory mechanisms are still in effect because cells of both strains become short. Hence, increased TADA incorporation is probably correlated with increased PG turn-over, rather than increased net synthesis, in the *murA*(S368P) cells. The authors may be correct, but only if cell size is (still) a reliable marker of cell growth.

a\) It is conceivable that the *murA*(S368P) mutant cells, though small, do keep on growing and dividing for longer (reach a higher OD) under starvation conditions. For example, depletion of some intermediate of LipidII synthesis might normally act as a general signal to stop/slow growth in wt cells, and this might no longer be very effective in the mutant. I recommend that the authors do some simple growth curves to ascertain that *murA*(S368P) cells indeed respond to starvation about the same as wt cells.

b\) Alternatively, and probably more likely, is that a fraction of (starving) *murA*(S368P) cells lyse, and that the viable cells feed on their released content. In fact, Figure 6---figure supplement 2 indicates that about half of the *murA*(S368P) cells die upon starvation, which is consistent with such a scenario. This will be difficult to detect by OD measurements. So I also recommend that the culture supernatants be tested for cytoplasmic content or, better yet, that starving wt and *murA*(S368P) cultures be tested for continued protein synthesis or for some other marker of metabolic activity, other than PG synthesis.

c\) The increased sensitivity of starved *murA*(S368P) cells to the different classes antibiotics ([Figure 6D](#fig6){ref-type="fig"}) would also be fully compatible with growth of these cells being less sensitive than wt to the starvation conditions used.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"A cytoplasmic peptidoglycan amidase homologue controls mycobacterial cell wall synthesis\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Detlef Weigel as the Senior editor, and three reviewers, one of whom is a member of our Board of Reviewing Editors. The manuscript has been improved but there are some remaining issues, as outlined below.

All three reviewers continue to be excited about the paper, but each agreed that some of the issues initially raised had not been adequately addressed. There were three major concerns and a number of additional concerns. After discussion among the reviewers and editors, it was agreed that all of these concerns would need to be fully addressed if the paper is to be considered further at *eLife*. Particularly for the major issues, additional experiments will be required, not just changes to the language and text. It is not our policy to consider multiple rounds of revision thus without a satisfactory resolution to the major issues below, we regret the paper will not be considered further.

Major issues:

1\) The authors did not adequately address original point \#7 about showing that MurA is not activated by CwlM(T347A)+PknB *in vitro*. The authors provide some reasons why they didn\'t do, or didn\'t include, the experiment, but these were unconvincing. It is a straightforward experiment and must be included. The authors state that they think the result might be that some activation still occurs, but this shouldn\'t preclude doing and reporting the experiment. In fact, if it turns out that CwlM(T347A) can still activate MurA, the authors will need to significantly revise their model and, consequently, other parts of the paper. For instance, they write when discussing the phenotypes of various mutants that \"...it seems likely that absence of phosphorylation on T374 inhibits the essential function of CwlM\". And one section states: \"We hypothesized that CwlM\~P activates MurA and that MurA is less active when CwlM is less phosphorylated, resulting in the inhibition of cell growth seen in the *cwlM* T374A mutant.\" If the biochemistry indicates that CwlM(T374A) can still activate MurA, such statements and hypotheses would be inaccurate. The authors should also, if the T374A mutant still activates, examine their truncated CwlM construct that lacks multiple putative phosphorylation sites.

2\) The original point \#8 needs to be more fully addressed. The response addressed the relative stoichiometries of the proteins, but the key issue is the extent of phosphorylation on CwlM. In other words, what percentage of CwlM is phosphorylated in this experiment? As noted in the original point, many bacterial phospho-proteins are not regulated such that 100% of the proteins are phosphorylated, so clarifying what happens to CwlM *in vitro* and *in vivo* is critical. On a related point, in subsection "CwlM\~P stimulates the enzymatic activity of MurA" and Figure S5: To establish the MurA/CwlM\~P ratio, you need to know the CwlM\~P/CwlM ratio first.

3\) The section on antibiotic tolerance during starvation ([Figure 6D](#fig6){ref-type="fig"}) needs additional attention. If we interpret the Materials and methods section correctly, antibiotics were added immediately upon transfer to HdB-C medium. At that point cells are not really starved yet, as indicated by the subsequent \~3-fold increase in OD ([Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}), and they haven\'t divided-up yet either as indicated by the \~10-fold increase in CFU ([Figure 6---figure supplement 1D](#fig6s1){ref-type="fig"}), when antibiotics are absent. The cultures in [Figure 6D](#fig6){ref-type="fig"} fail to show an increase in CFU, indicating the antibiotics prevent division of the long pre-shift cells ([Figure 6A](#fig6){ref-type="fig"}). These cells, in other words, have not had a chance to adjust to carbon-starvation before being hit with antibiotics.

a\) This raises the question: Is starvation even relevant here, or would you obtain similar results if you diluted cells in fresh 7H9 medium, and then added the antibiotics?

b\) The authors argument about antibiotic tolerance of starved cells would be stronger if cells were first allowed to normally respond to carbon starvation until CFU numbers have stabilized (\~20 hrs or so), before being hit with antibiotics.

c\) Another advantage is that treated cultures can then be directly compared to untreated control cultures, which are now absent (because they would show a large increase in CFU, I assume). This is relevant in light of the fact that *murA*(S368P) cells show diminished CFU in HdB-C medium, even in the absence of antibiotics ([Figure 6---figure supplement 1D](#fig6s1){ref-type="fig"}).

d\) Paragraph one, subsection "A regulatory system for PG biosynthesis contributes to drug tolerance": But you did not really test starved cells. What you tested was antibiotic sensitivity in cells during a transition from nutrient-rich to nutrient-poor conditions, a far more complex situation.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"A cytoplasmic peptidoglycan amidase homologue controls mycobacterial cell wall synthesis\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Detlef Weigel as the Senior editor, a Reviewing editor, and one reviewer.

We continue to be, in principle, inclined to accept the paper, provided you are willing to address the final concern of Reviewer \#3, which the Reviewing editor agreed was important for the final version of the paper:

Reviewer \#3:

This really is an interesting paper, and the addition of the ClwM phosphoablative mutants in [Figure 5E](#fig5){ref-type="fig"} renders the results and model more convincing. I am almost satisfied, except for one item which concerns the new [Figure 6D](#fig6){ref-type="fig"}.

1\) That MurA(S368P) cells fail to control PG synthesis normally is an important point in this paper.

In previous versions this was shown by TADA-labeling of WT and S368P cells that had been starved in HdB-C medium for 4 hrs. Cells were imaged and TADA labeling was quantified. One of the features that made the evidence compelling was the pattern of TADA accumulation in S368P cells (old panel 6C). This showed a clear accumulation of the label at constriction sites, which is where a lot of new PG synthesis takes place, providing visual evidence that most of the TADA-labeling was indeed likely to reflect PG synthesis, as expected.

In the present version of the manuscript, images of TADA-labeled cells are no longer shown. Instead, signals from a fluorescence cell sorter are shown in a new panel (6D), which also now supports the idea that S368P cells over-incorporate TADA during log-phase growth as well as up to 20 hrs after starvation in PBS. This is an important panel but, controls are needed and without cell images as provided in the previous version, virgin readers in particular may not be as convinced that the fluorescence signals plotted in the new panel 6D truly reflect new PG synthesis.

a\) Showing some TADA-labeled cells upon starvation in PBS would help convince readers.

b\) Paragraph four subsection "MurA activity is downregulated in the transition to starvation", and [Figure 6D](#fig6){ref-type="fig"}. The constant fluorescence seen with TADA-treated wt cells could be due to action of Ldts, as authors suggest. It could also be due to auto-fluorescence of the formaldehyde-fixed cells. So, how do curves look when TADA is omitted? It is not obvious this control was done, and it is formally even possible that S368P cells initially just auto-fluoresce more.

c\) Also, TADA might have some affinity for some cell feature, without being incorporated in PG. How would curves look when cells are fixed prior to incubation with TADA?

d\) Measurements of TADA-, or radiolabeled DAP-, incorporation in SDS-insoluble cell material would be more convincing.

10.7554/eLife.14590.018

Author response

*Essential revisions:*

1\) The claim that CwlM is non-enzymatic is not sufficiently rigorous. It is true that mutations in putative catalytic residues do not cause a loss of function, but this is rather weak; they need to show explicitly that the mutant protein is inactive biochemically. In addition, the mutagenesis is based on the analysis of a truncated B. subtilis protein and the paper cited describes numerous mutations not in the catalytic residues that also inactivated the protein. So, the linkage between specific mutations and lack of catalysis is tenuous. Additionally, according to Deng et al. it does have activity -- do you not agree and if so, why?

We have attempted to assay the enzymatic activity of wild-type CwlM without success. However, this negative result in no way proves that the (Deng et al., 2005) study is wrong. We were not able to exactly replicate their methods because the paper omitted many experimental details, so we may not have found the correct conditions yet. However, we feel that the question of whether CwlM is an enzyme is outside the scope of this paper, which is focused on its regulatory function. We rewrote several sections to clarify that we are not disputing that CwlM is an enzyme; we are merely showing that its enzymatic activity is not essential.

While there are other residues that can contribute to catalysis, per (Shida, 2001) the amino acids we mutated are essential. This is further confirmed in another citation (Prigozhin et al., 2013) which used both crystallography and biochemistry to prove that, in a related mycobacterial amidase Rv3717, E200, the functional equivalent of E331 in CwlM, is essential for enzymatic activity.

If the reviewers wish, we can include our negative data that showing a lack of activity for wild-type CwlM in the supplement. We are not including it now because we are not convinced that CwlM is inactive -- PG hydrolases are notorious for being difficult to get active *in vitro*, and for often requiring additional factors for activation.

*2) [Figure 1B](#fig1){ref-type="fig"}: why does depleting CwlM cause cells to die rather than just stop growing? If the model is that CwlM is simply required for promoting cell elongation, then why don\'t cells lacking CwlM just stop growing? As shown later, when CwlM phosphorylation is downregulated in starvation conditions, cells stop growing, but presumably are not dying, so reconciling these data is important. [Figure 1D](#fig1){ref-type="fig"}: Do CwlM-depleted cells phenocopy MurA-depleted cells (Xu et al., 2014) or show any shape changes or lysis?*

3\) Does the T374A mutant lose viability like the depletion strain? The doubling time is longer ([Figure 2C](#fig2){ref-type="fig"}) and the cells don\'t grow polarly ([Figure 2F](#fig2){ref-type="fig"}) but what about viability?

Our model is that, in the mutant, PG synthesis is no longer tied to the synthesis of other components of the cell wall leading to a loss of cell wall integrity. We have added text to the Discussion to address this issue.

The *cwlM* T374A strain had very low plating efficiency when it was initially constructed for the experiments in [Figure 2](#fig2){ref-type="fig"}. We did not measure CFUs in this strain because it is so unstable that we get suppressors within a day of passaging the culture. The low viability of this strain is apparent in the data from [Figure 4B](#fig4){ref-type="fig"}, where we get almost no transformants that have swapped the wild type allele for the T374A allele in a background with wild type MurA. We were only able to get CwlM T374A allele swaps initially in the strains shown in [Figure 2](#fig2){ref-type="fig"} because we used a parental strain that had the tetR repressor on the L5 vector with CwlM. The *cwlM* promoters both have tetO operators in their promoters. Any transformants that retained the wild-type *cwlM* also retained *tetR*, and the expression of CwlM was repressed. Thus, those strains were built in such a way as to 'force' the allele swap and loss of the wild-type allele. In the allele swaps we did for [Figure 4](#fig4){ref-type="fig"}, there was no tetR -- this allowed us to assess the relative frequency of 'correct' allele swaps as a metric for the viability of the resulting strains. We included an explanation of this interpretation in the Discussion, and expanded our explanation of the method Materials and methods.

*4) The authors cite Kall et al. 2007 as evidence that CwlM lacks a secretion signal, but that paper is only a citation to a prediction server and furthermore, running CwlM through that server yields the prediction of a non-cytoplasmic (i.e., secreted) protein. The determination of compartmental localization using the MTSEA/MTSET is also confusing and should be clarified. The authors state in the legend to [Figure 2](#fig2){ref-type="fig"} that \"scores \>1 are periplasmic, \<1 are cytoplasmic\", so why does mRFP, unambiguously a cytoplasmic protein, have a value of.84* ± *. 40. In addition to a better explanation of the MTSEA/MTSET approach, the authors should consider a more traditional approach, such as fractionation, unless it is experimentally too demanding. And, perhaps more importantly, is it possible that some CwlM is present in each compartment? Unless this can be categorically ruled out, the authors should adjust their language about the cellular location of CwlM throughout the paper, including in the title.*

The Phobius secretion signal prediction site does not actually predict that CwlM has a secretion signal. It does, for some reason, predict that it is periplasmic, but it predicts that many cytoplasmic proteins are periplasmic, including MurA, GcvH, ParA and FhaA, all of which have established cytoplasmic functions. We were referring to the secretion signal prediction, not the other prediction that Phobius conducts, which seems to be quite faulty. We agree that this is confusing, so we have replaced the Phobius prediction with a reference to the SignalP4.0 site, which also indicates that CwlM lacks a secretion signal.

We have conducted fractionation experiments with CwlM, and we find it in the 'cytoplasmic' fraction. However, because there is no way to remove the periplasm as in *E. coli*, that fraction also contains soluble periplasmic proteins that are not tightly associated with the cell wall or the membrane. We were thus not convinced by that experiment, and sought to use other methods. The only published method of determining compartmental location of mycobacterial proteins is PhoA fusions (Lim et al., 1995). Unfortunately, every fusion protein we made to CwlM, including NT, CT and internal fusions of PhoA or fluorescent proteins, were cleaved by the abundant mycobacterial proteases. Thus, we had to develop a new method to determine compartmental localization. We adapted the substituted cysteine accessibility method for this purpose. The cytoplasmic control that we had shown in the original manuscript, mRFP, was partially cleaved, so there were faint extra bands on the gel that confused the result. We have used a new cytoplasmic control, phosphoglycerate mutase (Pgm), which gives us a cleaner result. We also optimized and repeated the assay, and present the new data in [Figure 2G](#fig2){ref-type="fig"}.

Because there is no perfect method for establishing protein localization, it remains possible that some CwlM is periplasmic, though we suspect that this is unlikely. But our conclusion is that the essential role of CwlM is in the cytoplasm, a conclusion that we feel is consistent with our title.

5\) T374 is phosphorylated and the T374A mutant displays some of the phenotypes associated with a cwlM depletion strain. But formally such data alone do not support the conclusion that \"CwlM is a cytoplasmic protein whose essential function is activated by phosphorylation.\" It could be well be that the threonine at position 374 is important for its essential function but not because it must be phosphorylated. At a bare minimum, the authors need to be more precise in their language. Preferably, they would address this experimentally -- for example, by testing whether a phosphomimetic (T374D or T374E) allele is hyperactive with respect to activating MurA -- has this been tried?

Thank you for the suggestion. Based on this idea, we did construct strains with "phosphomimetic" mutations at the phosphorylated CwlM sites (threonine to aspartates) and we found that the phenotypes were the same as the phospho-ablative mutations. This is not uncommon -- amino acid replacements do not always mimic the effect of phosphorylation. We agree with the reviewers that the mutation could alter CwlM function in unexpected ways, and we have changed the text to acknowledge that we cannot be sure of the importance of phosphorylation in regulating CwlM function based on this genetic data alone.

*6) Do constitutively active forms of CwlM rescue the essentiality of pknB mutants? And does the S368P mutation in murA bypass essentiality of pknB?*

This is an interesting question. As described above, we cannot make constitutively active CwlM mutants. But, while the idea that CwlM is the substrate that makes PknB essential is intriguing, we suspect that it is unlikely. PknB has been shown to phosphorylate a broad array of critical proteins and is thought to be a "master regulator" of other protein kinases (Baer et al., 2014). And, while the experiment would be interesting, it is technically difficult and would take a very long time to perform it rigorously. Ultimately, given the low probability of success, we would prefer not to pursue this question. We have rewritten sections in the Discussion to clarify our model that PknB likely regulates many essential proteins.

7\) [Figure 5](#fig5){ref-type="fig"}: The activation of MurA by CwlM+PknB is convincing, although the authors need to also show that MurA is not activated by CwlM(T347A)+PknB to ensure that PknB isn\'t having some other effect independent of T347 phosphorylation. Also, does CwlM(T347A) no longer activate MurA, as predicted from the genetics?

We agree that the controls for the biochemistry experiments are critical for interpreting these data. To address this concern we have repeated our controls, moved them from [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"} to [Figure 5](#fig5){ref-type="fig"}, and rewritten several sections to address the controls more clearly. A control with CwlM+PknB+ATP but no MurA shows that CwlM\~P alone cannot synthesize EP-UDP-GlcNAc, and a control with PknB+ATP+MurA but no CwlM shows that the activation is specific to CwlM's phosphorylation, and that PknB does not activate MurA in the absence of CwlM. Finally, the control that was already in [Figure 5](#fig5){ref-type="fig"} is unphosphorylated CwlM that is incubated with PknB but not ATP. Together these controls show that phosphorylated CwlM activates MurA. As the reviewers point out, they do not establish that the activating phosphate is restricted to T374 (*Msmeg*)/ T382 (*Mtb*). We have rewritten sections in the Results and Discussion to make it clear that the other sites on the C-terminal tail are also phosphorylated and that these could contribute to MurA activation.

The reason we did not do the MurA assays with CwlM T382A (the TB analog of CwlMT374A) is that, as the reviewers mention in point 5, the T to A mutation could affect protein function in a way that is independent of phosphorylation. In addition, we did a few experiments that suggest that the other phosphorylation sites we found could still contribute to CwlM's activation of MurA, though to a lesser extent that T374. We include mention these points in our revised draft:

1\) *in vitro* phosphorylated CwlMTB is phosphorylated on the same sites (T382, 384, 386) as in vivo phosphorylated CwlM~SM~ (T374, 376, 378). We performed mass spectrometry to show this, and have added mentions of this in the text and included an annotated alignment in [Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}. This indicates that the pattern of phosphorylation on the C-terminal tail of CwlM is conserved between *Mtb* and *Msmeg*, which along with the strong sequence conservation of the C-terminal tail across actinomyecetes ([Figure 2B](#fig2){ref-type="fig"}), supports the idea that the entire C-terminal tail is functionally important. Thus we think it likely that the other phosphorylation sites contribute to MurA activation, and we would therefore expect that the CwlM T382A mutant incubated with PknB and ATP would still activate MurA more than the unphosphorylated protein.

2\) A strain with alanine substitutions at CwlM T376, T378, K362 and K369 grows more slowly than wild-type. This indicates that phosphorylation at the other sites could, in combination, contribute to the function of CwlM, but that these other sites have less of an effect in isolation. We have included the growth rate data for this strain in [Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}.

Finally, is the basal level activity of the Mtb version of MurA(S368P) significantly higher than that of wt MurA, and/or is unphosphorylated CwlM sufficient to stimulate its activity?

We thank the reviewers for pushing us to do a difficult experiment that really should have been done. While the original biochemistry was performed with Mtb proteins, we were unable to purify MurA S368P from *Mtb* -- it was not soluble. In response to this suggestion, we therefore used the *Msmeg* MurA, which is 87% identical and 95% similar to the protein from *Mtb*. We were able to purify soluble *Msmeg* MurA S368P, so we conducted endpoint assays of the WT and mutant MurA in the various CwlM conditions. We present the data in [Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}. The data show that MurA S368P has a higher basal activity level than MurA WT, but that it is also activated by CwlM\~P. We have included mention of these data in the text.

8\) In the experiment in [Figure 5](#fig5){ref-type="fig"} showing the effect of phosphorylation on the ability of CwlM to activate MurA, they need to characterize the stoichiometry of phosphorylation -- the data indicate that this is quite high, but that would be the exception for bacterial phosphoproteins. Also, as noted above, they should try the phosphomimetic mutant of T374 to confirm the genetic data from [Figure 2E](#fig2){ref-type="fig"}.

We used the TB proteins to do this experiment using endpoint assays, and found, to our surprise, that the stoichiometry of the CwlM\~P:MurA reaction appears to be 2:1. We present these data in [Figure 5---figure supplement 1E](#fig5s1){ref-type="fig"} and mention them in the text. This implies that the active complex is possibly a trimer. We hope to explore the nature of this multimer and the detailed molecular mechanism of MurA activation more in future work.

*9) [Figure 6B](#fig6){ref-type="fig"} suggests that the change in CwlM phosphorylation is because of a change in PknB levels, but the authors need to verify this by showing that constitutive expression of PknB maintains CwlM phosphorylation upon starvation.*

We have rewritten several sections to clarify our hypothesis that, while PknB is probably primarily responsible for phosphorylating CwlM, there are likely other proteins that dephosphorylate CwlM in starvation. The reduction in CwlM phosphorylation that we observe in [Figure 6B](#fig6){ref-type="fig"} is too rapid for transcriptional regulation of pknB alone to be responsible for that change. It is likely that there is a phosphatase that actively removes phosphates from CwlM: this is a question we hope to address in future studies. Overexpressing pknB in starvation may not give the desired result because, in addition to being transcriptionally regulated, pknB is also post-translationally regulated (Baer et al., 2014), so the overexpressed pknB would likely not be active.

*10) [Figure 6C, D](#fig6){ref-type="fig"}, subsection "MurA activity is downregulated in starvation" -- The TADA incorporation experiments ([Figure 6C](#fig6){ref-type="fig"}) suggest that the murA(S368P) cells still produce PG upon starvation when the wt cells do not (so much). The authors suggest that growth inhibitory mechanisms are still in effect because cells of both strains become short. Hence, increased TADA incorporation is probably correlated with increased PG turn-over, rather than increased net synthesis, in the murA(S368P) cells. The authors may be correct, but only if cell size is (still) a reliable marker of cell growth.*

*a) It is conceivable that the murA(S368P) mutant cells, though small, do keep on growing and dividing for longer (reach a higher OD) under starvation conditions. For example, depletion of some intermediate of LipidII synthesis might normally act as a general signal to stop/slow growth in wt cells, and this might no longer be very effective in the mutant. I recommend that the authors do some simple growth curves to acertain that murA(S368P) cells indeed respond to starvation about the same as wt cells.*

We agree with the reviewers that this seems very likely. We have done these growth curves in carbon-limited media and see a slight but statistically insignificant difference, which we have now added to [Figure 6---figure supplement 1C,D](#fig6s1){ref-type="fig"}. The *murA* S368P strain may reach a slightly higher OD during the transition to starvation, before starting to die more in stationary phase. We have mentioned this in the Results and the Discussion.

*b) Alternatively, and probably more likely, is that a fraction of (starving) murA(S368P) cells lyse, and that the viable cells feed on their released content. In fact, [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"} indicates that about half of the murA(S368P) cells die upon starvation, which is consistent with such a scenario. This will be difficult to detect by OD measurements. So I also recommend that the culture supernatants be tested for cytoplasmic content or, better yet, that starving wt and murA(S368P) cultures be tested for continued protein synthesis or for some other marker of metabolic activity, other than PG synthesis.*

We performed this experiment by blotting the *murA* S368P and WT culture supernatants for rpoB during carbon starvation. We found that the mutant culture had more rpoB in the supernatant than the WT, and have reported this in the text and in [Figure 6---figure supplement 1E](#fig6s1){ref-type="fig"}. We also include an acknowledgment that the higher TADA staining could be due to the extra nutrients available to the mutant cells due to lysis.

*c) The increased sensitivity of starved murA(S368P) cells to the different classes antibiotics ([Figure 6D](#fig6){ref-type="fig"}) would also be fully compatible with growth of these cells being less sensitive than wt to the starvation conditions used.*

We agree that this is a possibility, and have added text about this in the Discussion.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

*All three reviewers continue to be excited about the paper, but each agreed that some of the issues initially raised had not been adequately addressed. There were three major concerns and a number of additional concerns. After discussion among the reviewers and editors, it was agreed that all of these concerns would need to be fully addressed if the paper is to be considered further at eLife. Particularly for the major issues, additional experiments will be required, not just changes to the language and text. It is not our policy to consider multiple rounds of revision thus without a satisfactory resolution to the major issues below, we regret the paper will not be considered further.*

*Major issues:*

*1) The authors did not adequately address original point \#7 about showing that MurA is not activated by CwlM(T347A)+PknB* in vitro. *The authors provide some reasons why they didn\'t do, or didn\'t include, the experiment, but these were unconvincing. It is a straightforward experiment and must be included. The authors state that they think the result might be that some activation still occurs, but this shouldn\'t preclude doing and reporting the experiment. In fact, if it turns out that CwlM(T347A) can still activate MurA, the authors will need to significantly revise their model and, consequently, other parts of the paper. For instance, they write when discussing the phenotypes of various mutants that \"...it seems likely that absence of phosphorylation on T374 inhibits the essential function of CwlM\". And one section states: \"We hypothesized that CwlM\~P activates MurA and that MurA is less active when CwlM is less phosphorylated, resulting in the inhibition of cell growth seen in the cwlM T374A mutant.\" If the biochemistry indicates that CwlM(T374A) can still activate MurA, such statements and hypotheses would be inaccurate. The authors should also, if the T374A mutant still activates, examine their truncated CwlM construct that lacks multiple putative phosphorylation sites*.

We have now conducted MurA activation assays with CwlM T382A (The TB analog of CwlM T374A from Msmeg) and with CwlM T382A T384A T386A. The results with the *Mtb* proteins mirror the results from the *Msmeg* genetic experiments: CwlM T382A in an active kinase reaction has very low MurA stimulation activity, and CwlM T382A T384A T386A behaves just like unphosphorylated CwlM. We include these data in [Figure 5E](#fig5){ref-type="fig"}.

*2) The original point \#8 needs to be more fully addressed. The response addressed the relative stoichiometries of the proteins, but the key issue is the extent of phosphorylation on CwlM. In other words, what percentage of CwlM is phosphorylated in this experiment? As noted in the original point, many bacterial phospho-proteins are not regulated such that 100% of the proteins are phosphorylated, so clarifying what happens to CwlM* in vitro *and* in vivo *is critical. On a related point, in subsection "CwlM\~P stimulates the enzymatic activity of MurA" and [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}: To establish the MurA/CwlM\~P ratio, you need to know the CwlM\~P/CwlM ratio first.*

We used a 2D gel to assess how much his-CwlM is phosphorylated in the in vitro assays. Upon phosphorylation by PknB, we see a shift of the entire his-CwlM spot to a lower isoelectric point. We interpret this to mean that the vast majority of the protein is phosphorylated on at least one site. Because the 2D gel cannot tell us exactly how much his-CwlM is in each of the 7 possible combinatorial phosphorylation configurations, there remain uncertainties. We appreciate that these uncertainties mean that the kinetic constants we present in [Figure 5](#fig5){ref-type="fig"} actually represent a mixture of different rates: it is likely that CwlM phosphorylated at T382 has a different rate than CwlM phosphorylated at T384 and T386. We include language to explain this, and to emphasize that the constants are presented for broad comparisons, and are not intended to represent the precise rate of a single intermolecular interaction.

*3) The section on antibiotic tolerance during starvation ([Figure 6D](#fig6){ref-type="fig"}) needs additional attention. If we interpret the Materials and methods section correctly, antibiotics were added immediately upon transfer to HdB-C medium. At that point cells are not really starved yet, as indicated by the subsequent \~3-fold increase in OD ([Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}), and they haven\'t divided-up yet either as indicated by the \~10-fold increase in CFU ([Figure 6---figure supplement 1D](#fig6s1){ref-type="fig"}), when antibiotics are absent. The cultures in [Figure 6D](#fig6){ref-type="fig"} fail to show an increase in CFU, indicating the antibiotics prevent division of the long pre-shift cells ([Figure 6A](#fig6){ref-type="fig"}). These cells, in other words, have not had a chance to adjust to carbon-starvation before being hit with antibiotics.*

*a) This raises the question: Is starvation even relevant here, or would you obtain similar results if you diluted cells in fresh 7H9 medium, and then added the antibiotics?*

*b) The authors argument about antibiotic tolerance of starved cells would be stronger if cells were first allowed to normally respond to carbon starvation until CFU numbers have stabilized (\~20 hrs or so), before being hit with antibiotics.*

*c) Another advantage is that treated cultures can then be directly compared to untreated control cultures, which are now absent (because they would show a large increase in CFU, I assume). This is relevant in light of the fact that murA(S368P) cells show diminished CFU in HdB-C medium, even in the absence of antibiotics ([Figure 6---figure supplement 1D](#fig6s1){ref-type="fig"}).*

*d) Paragraph one, subsection "A regulatory system for PG biosynthesis contributes to drug tolerance": But you did not really test starved cells. What you tested was antibiotic sensitivity in cells during a transition from nutrient-rich to nutrient-poor conditions, a far more complex situation.*

The reviewers' comments made us realize that there were several confusing things about [Figure 6](#fig6){ref-type="fig"}. First, we had done starvation experiments in both PBS starvation and in carbon-only starvation in HdB media. The no-drug CFU experiment was also done in low carbon media, while the drug experiments were done in no carbon media. We decided to redo all the experiments in PBS starvation for the sake of consistency.

Secondly, we needed to identify the conditions in which the post-translational regulation of MurA affects cell physiology. We have now used the D-alanine dye TADA to assess PG metabolism in the WT and the over-active *murA* S368P strain in log phase and during 24 hours of PBS starvation. We used flow cytometry to measure the level of fluorescent staining with this dye at several time points ([Figure 6D](#fig6){ref-type="fig"}). We found that the difference in TADA staining is highest in log phase and early starvation, and decreases in late starvation. We think this means that the post-translational regulation of MurA is likely to be important during environmental transitions.

Finally, we redid the CFU killing experiments in log phase growth in 7H9, in the transition to PBS starvation, and in deep starvation. The results are what we expect from the TADA staining experiment: we see the biggest defect in viability of the *murA* S368P strain in log phase and during the transition to starvation. In the 7H9 experiments the data are difficult to interpret because some of the replicates developed antibiotic resistance over the course of the experiment. We changed the wording throughout to indicate that the MurA regulatory system is important during the transition to starvation, and we see differences in antibiotic tolerance then.

When we did the starvation experiments with carbon starvation in HdB we had seen a viability/ growth defect of the *murA* S368P mutant during starvation alone. However, we did not observe this defect reproducibly in PBS starvation, so we have removed mention of this defect throughout, and we focus only on the antibiotic sensitivity phenotype.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

*This really is an interesting paper, and the addition of the ClwM phosphoablative mutants in [Figure 5E](#fig5){ref-type="fig"} renders the results and model more convincing. I am almost satisfied, except for one item which concerns the new [Figure 6D](#fig6){ref-type="fig"}.*

*1) That MurA(S368P) cells fail to control PG synthesis normally is an important point in this paper.*

*In previous version, this was shown by TADA-labeling of WT and S368P cells that had been starved in HdB-C medium for 4 hr. Cells were imaged and TADA labeling was quantified. One of the features that made the evidence compelling was the pattern of TADA accumulation in S368P cells (old panel 6C). This showed a clear accumulation of the label at constriction sites, which is where a lot of new PG synthesis takes place, providing visual evidence that most of the TADA-labeling was indeed likely to reflect PG synthesis, as expected.*

*In the present version of the manuscript, images of TADA-labeled cells are no longer shown. Instead, signals from a fluorescence cell sorter are shown in a new panel (6D), which also now supports the idea that S368P cells over-incorporate TADA during log-phase growth as well as up to 20 hrs after starvation in PBS. This is an important panel but, controls are needed and without cell images as provided in the previous version, virgin readers in particular may not be as convinced that the fluorescence signals plotted in the new panel 6D truly reflect new PG synthesis.*

*a) Showing some TADA-labeled cells upon starvation in PBS would help convince readers.*

[Figure 6C](#fig6){ref-type="fig"}.

*b) Paragraph four subsection "MurA activity is downregulated in the transition to starvation", and [Figure 6D](#fig6){ref-type="fig"}. The constant fluorescence seen with TADA-treated wt cells could be due to action of Ldts, as authors suggest. It could also be due to auto-fluorescence of the formaldehyde-fixed cells. So, how do curves look when TADA is omitted? It is not obvious this control was done, and it is formally even possible that S368P cells initially just auto-fluoresce more.*

[Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}.

*c) Also, TADA might have some affinity for some cell feature, without being incorporated in PG. How would curves look when cells are fixed prior to incubation with TADA?*

[Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}.

*d) Measurements of TADA-, or radiolabeled DAP-, incorporation in SDS-insoluble cell material would be more convincing.*

[Figure 6---figure supplement 1D](#fig6s1){ref-type="fig"}. You can see from the inset that, in the mutant, the SDS insoluble fraction stains more brightly even by eye.
